Wantstats
IndustriesCompaniesCharts & Stats
Leads DBAdvisoryPricingContact us
Login
/Company Profiles

Deep Intelligence Across Industries

All CompaniesFortune 500Aerospace & Defense iconAerospace & DefenseAgricultureAutomotive iconAutomotiveFinancial Services iconFinancial ServicesChemicals & Materials iconChemicals & MaterialsConsumer Goods iconConsumer GoodsEnergy & Power iconEnergy & PowerEquipment & Machinery iconEquipment & MachineryFood & Beverages iconFood & BeveragesHealthcare & Pharma iconHealthcare & PharmaInformation Technology iconInformation TechnologyManufacturing & ConstructionMRO iconMROProfessional Services iconProfessional ServicesSemiconductors

Showing 14441 companies

Orthocell

Orthocell Limited

Premium
Information Technology

Orthocell is a Perth-based regenerative medicine company that has completed its transition from research to commercial operations. Its business is built on SMRT™, a proprietary process that preserves the native structure of collagen without crosslinking or chemical modification. Two collagen medical devices on that platform generate most of its revenue. Remplir™ is a nerve wrap for peripheral nerve repair, and Striate+™ is a dental guided bone regeneration membrane licensed globally to BioHorizons, part of the Henry Schein group. Orthocell owns its intellectual property and manufactures every device at an ISO 13485-certified facility in Perth, which lets it keep the manufacturing margin while choosing a different route to market in each country. The investment case rests on converting the April 2025 FDA 510(k) clearance for Remplir into repeat US surgical use in a market the company sizes at US$1.6bn. Supporting legs are UK/EU approval, a new nerve-sparing prostate surgery indication and a tendon pipeline (SmrtWrap™). The balance sheet is well funded (A$44M) but the company is still loss-making, with an FY26 net loss of A$13.9M. --- ### Company's own description (FY2026 Annual Report, paraphrased) In its FY2026 Annual Report, Orthocell describes itself as a company that develops, manufactures and commercialises regenerative medicine products for repairing nerve, bone, tendon and cartilage tissue. Its products are designed to work with the body's natural healing, to simplify complex surgery, to shorten operating time and to produce consistent results. It names Remplir™ (collagen nerve wrap) and Striate+™ (resorbable collagen membrane for guided bone and tissue regeneration) as its principal commercial products. It also markets OrthoACI™, an autologous cartilage cell therapy, in Australia, and is developing SmrtWrap™, a collagen tendon repair device. All devices are made at its ISO 13485-certified Perth facility from Australian-sourced collagen raw material and supplied internationally through specialist distributors, a global partner (BioHorizons) and an in-house US commercial team. ### Business model The FY2026 Annual Report describes an integrated model resting on three capabilities. 1. **Proprietary technology.** The SMRT™ collagen processing platform, developed over more than a decade, is fully owned by Orthocell and carries no royalties on device sales. 2. **Owned Australian manufacturing.** Every Remplir and Striate+ unit sold worldwide is made in Perth. The devices have a three-year shelf life, so production can be centralised and shipped to North America, Europe, Asia-Pacific and Latin America. CEO Paul Anderson summarises the rationale as owning the manufacturing so that the company also owns the manufacturing margin. 3. **Market-specific routes to market:** - **Striate+:** an exclusive 25-year global licence and supply arrangement with BioHorizons Implant Systems. Orthocell is the contract manufacturer and BioHorizons sells under its own commercial infrastructure. About 60,000 units were manufactured for BioHorizons in FY26. - **Remplir in Australia, New Zealand and Singapore:** exclusive distribution by Device Technologies Group. - **Remplir in other international markets:** specialist distributors, including MontsMed (Hong Kong), two distributors in Canada, LEDA Orthopaedics (UK, pre-launch) and MediTime (Thailand). - **Remplir in the United States:** a hybrid model. An internal team covering sales, medical education, marketing and medical affairs supports 18 specialist distributors across more than 20 states, about 50% population coverage at 30 June 2026. ### Revenue model and mix Orthocell earns revenue from four sources: **Product sales (point in time):** Remplir sold to distributors and hospitals, Striate+ sold to BioHorizons, and OrthoACI cell therapy procedures in Australia. - **Licence and contract revenue (deferred, recognised over time):** BioHorizons paid an upfront US$16M (A$23.1M) on signing in July 2022. It sits as a contract liability that is released to revenue over time. The balance was A$16.07M at 30 June 2025 (A$2.30M current, A$13.77M non-current) and A$13.78M at 30 June 2026 (A$2.31M current, A$11.46M non-current), which implies about A$2.3M of non-cash revenue recognised each year. That run-rate is the analyst's inference from the movement in the balance sheet line. **Finance income:** A$1.82M in FY26, interest on cash and term deposits. It sits outside statutory revenue but is included in management's headline "revenue". **Grant income:** principally the Australian R&D Tax Incentive refund, A$3.0M in FY26, booked below gross profit. The company has no subscription or service revenue. A full statutory split of FY26 revenue by product (Remplir, Striate+ manufacturing, licence amortisation, OrthoACI) is not publicly disclosed in the documents reviewed. The disclosed data points are: - Australian Remplir revenue exceeded A$1.5M in the June 2026 quarter alone, from more than 1,000 procedures. - US Remplir revenue was A$0.33M in the June 2026 quarter and A$0.92M cumulative since launch. - International Remplir sales were more than 9% of quarterly revenue in Q4 FY26. ### Value chain position, customers and end-markets Orthocell is vertically integrated from raw collagen processing through to the finished sterile device. It does not run its own sales operations outside the US. **Direct customers:** - distributors (Device Technologies, MontsMed, LEDA, MediTime, US specialist distributors); - a strategic licensee (BioHorizons); - hospitals in the US, which buy after Value Analysis Committee (VAC) approval. **End users:** - microsurgically trained hand, plastic and orthopaedic surgeons (peripheral nerve); - urologists (nerve-sparing radical prostatectomy); - dental implant surgeons and periodontists (Striate+); - orthopaedic surgeons (OrthoACI and the tendon programmes). **End-markets:** peripheral nerve repair, which the company sizes at US$1.6bn in the US and about US$750M in the UK/EU; dental guided bone regeneration membranes (about US$735M globally for Striate+'s addressable segments); tendon repair; and cartilage repair. ### Independent characterisation Orthocell is best understood as a sub-scale but commercially validated single-platform biomaterials manufacturer. Its value depends overwhelmingly on Remplir's US adoption curve. The Striate+ business is effectively a contract manufacturing annuity plus licence amortisation. It brings external validation from a Henry Schein subsidiary and production scale, but Orthocell has limited control over its growth. The Australian Remplir franchise proves the product commercially. Its scale (370 surgeons and 239 hospitals since launch, more than 1,000 procedures a quarter) is the strongest evidence in the dossier. The US is still in the market-access phase. In FY26, 70 hospitals and 76 surgeons generated only about A$0.9M of cumulative revenue, and management itself frames the next year as a test of repeat use. The company is not yet a growth-at-scale medtech. It is funded, de-risked on regulatory grounds, and now exposed mainly to commercial execution risk.

RevenueN/A
EmployeesN/A
Market CapN/A
Founded2006
Murdoch, Australia

Unlock Verified Contacts

Access verified employee contacts

Decision-maker information to support your sales, lead generation, and business development. 5 users, 5,500 credits a month with rollover, and one credit per contact email.

USD650/mo
Buy Now

Powering the world's best teams.
From next-gen startups to established enterprises.

Google logo
Amazon logo
Microsoft logo
Intel logo
Neste logo
McKinsey & Company logo

What our clients say

Trusted by forward-thinking businesses
for data-driven intelligence

Noah Malgeri
Noah Malgeri

Co-Founder, Mojave Rail Fabrication Limited

This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job.
MR
Michael Robert

Manager, JavolVision

Thanks, I am so happy that we worked together. Maybe we still can work together in the future.
Joseph Aguayo
Joseph Aguayo

Sales Operations & Pricing Manager, Intel

Thanks. It's been a pleasure working with you, please use me as reference with any other Intel employees.
BL
Bong Lau

Sales Leader, Bamberg

We bought your "2025 report" in 2020. Everything is fine and very good.
Peter Groot Koerkamp
Peter Groot Koerkamp

Account and Business Manager, EFS-Holland BV

Thanks for sending the report it gives us a good global view of the Betaïne market.
Younghwan Choi
Younghwan Choi

Senior Retail Manager, LG Chem

We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.
MI
Mark Irwin

Management Consultant, Level 21

I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.
RK
Rob Kooiker

Group Product Manager HVAC & Fire Protection GMA, Rockwool

I have been reading the first document or the study, the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!
JL
Jason Lee

R&D Director, Seojin

Thanks for your great support. Appreciate it. Well received report. It helps us to understand market well. We're planning other area of survey in the future, let's keep in touch.
AM
Akif Moroglu

Strategy & Business Development Director, Dogan Holding

We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.
Wantstats logo

Move faster. Think smarter. Win bigger.

Join our data driven community.

© 2026 All rights reserved by Wantstats Research and Media Pvt Ltd

footer vector

Pages

  • About
  • News
  • Charts & Stats
  • Contact
  • Ecosystem pricing
  • Privacy policy

Address

Wantstats Research and media Pvt. Ltd, Office No 104, Pentagon 4,
Magarpatta City, Pune - 411028,
Maharashtra, India.

Contact

support@wantstats.com

Follow Us

Follow Wantstats on FacebookFollow Wantstats on InstagramFollow Wantstats on LinkedInFollow Wantstats on YouTubeFollow Wantstats on WhatsApp
Orora

Orora Limited

Premium
Information Technology

Orora is now a focused, two-substrate beverage packaging company. It makes aluminium cans in Australia and New Zealand, and premium and luxury glass bottles worldwide through Saverglass and the Gawler plant in South Australia. Since 2023 it has transformed itself: it bought Saverglass (France) from Carlyle for an enterprise value of about €1.29bn, then exited its largest legacy business, North American distribution (OPS), by selling it to Veritiv for US$1.2bn. The result is a business with structurally advantaged Australasian can franchises and a globally recognised premium spirits and wine bottle brand. The Cans business benefits from steady substrate shift to aluminium and from new beverage categories, and has just finished a multi-year capacity build. Saverglass offers long-run premiumisation exposure but is currently in a cyclical and geopolitical trough. That trough produced a €449.7m impairment in FY26 and forced a reset of acquisition-era expectations. The investment case now turns on Cans compounding, Saverglass recovery, and capital returns funded from a balance sheet with modest leverage (1.2x). --- ### Company self-description In its FY25 and FY26 annual reports, Orora describes itself as a global leader in the design and manufacture of glass bottles and aluminium cans. It says the transformed portfolio has leading positions in cans and in premium glass. Management calls the FY26 business a focused beverage packaging business. Following the OPS sale, it reports on a "Global Glass and Cans" structure, which it says better represents the entire portfolio (FY25 Investor Results Release, 14 Aug 2025). ### What the company does Orora runs three operating businesses, organised into two reporting pillars: 1. **Orora Cans (Australasia).** Manufactures aluminium beverage cans and ends in multiple sizes, with decoration including the Helio digital direct-to-can printing service. It serves brewers, carbonated soft drink (CSD) bottlers, energy drink brands, alternative and functional beverage makers, and ready-to-drink (RTD) producers. FY26 revenue was A$880.0m and EBIT A$111.4m. 2. **Saverglass (Global Glass, premium/luxury).** A French-headquartered maker of high-end glass bottles for spirits (tequila, mezcal, bourbon, vodka, cognac, gin and others) and for wines and champagne/crémant. It also offers in-house decoration and customisation. FY26 revenue was €617.2m (A$1,061.4m) and EBIT €62.8m (A$108.7m). 3. **Gawler Glass (Global Glass, Australia).** A large glass container plant at Gawler, South Australia, making wine and beer bottles mainly for the Australian market. It also runs a glass beneficiation (cullet) plant. FY26 revenue was A$284.5m and EBIT A$28.1m. ### Business and revenue model **Product mix:** Revenue is essentially 100% manufactured products. There is no material subscription or licensing revenue. Decoration, design and customisation services (Saverglass decoration; Helio digital print for cans) are bundled into product pricing rather than reported as service revenue. **Contracting:** Cans and Gawler operate under multi-year supply agreements with large brewers and beverage groups. These include aluminium cost pass-through and contracted price escalation; the FY26 release notes "contracted price increases" at Gawler. Saverglass runs a large-customer contract model with "built-in inflation / energy price formulas" (9 April 2026 trading update). It also carries a meaningful share of customer-owned inventory. **Cost pass-through:** Aluminium is passed through in Cans. FY26 Cans revenue grew 13.3%, or 10.5% excluding aluminium pass-through. Energy is partly indexed in Saverglass contracts. **Capital intensity:** The business is capital-intensive. Furnaces need periodic rebuilds (Gawler G3; Saverglass Ghlin) and can lines are added in large increments (Revesby Line 2; the Rocklea 375ml line, about A$140m in total). FY26 base capex was A$85.9m and growth capex A$108.4m. ### Value chain position Orora is a midstream converter. It buys aluminium coil (Cans) and raw materials such as sand, soda ash, limestone and cullet, plus energy (Glass). It sells finished containers to brand owners and fillers. It does not fill, distribute or own beverage brands. In Saverglass, the value-add sits in design, mould-making, ultra-premium glass quality ("extra-flint") and decoration, which gives some pricing power at the luxury end. ### Customer types and end-markets | End-market | Business | FY26 commentary (source: FY26 Investor Results Release) | |---|---|---| | Energy drinks, CSD, alternative soft drinks | Cans | Strongest volume growth categories in FY26 | | Beer | Cans, Gawler | Good growth in cans; continued decline in glass beer bottles (substrate shift to cans) | | Premium and ultra-premium spirits (tequila, mezcal, bourbon, vodka) | Saverglass | Spirits were 54% of FY26 Saverglass volume (+2ppt); 48% in 2H26 | | Still wine, champagne, crémant | Saverglass, Gawler | Wine and champagne mix rose in 2H26; crémant was a growth driver; Australian domestic and export wine demand challenged | | RTDs | Cans | Part of the "new categories" driving aluminium demand | ### Independent characterisation Orora is really two businesses with very different economics under one listed shell: 1. **Cans** is a high-utilisation, low-volatility infrastructure-like franchise. It sits in a concentrated Australian market, faces structural demand tailwinds, and earns EBIT margins of 12.7–13.4%. It has just come off five years of continuous 24/7 operation. 2. **Saverglass** is a cyclical luxury-goods supplier. Its earnings are levered to US spirits demand (notably tequila), European wine and champagne, tariff regimes, and energy costs. It is currently deep in a destocking-to-downtrading cycle, compounded by the 2026 Middle East conflict, which forced its UAE plant into "closed loop" mode. Gawler is a sub-scale, contracting domestic glass asset. It has been right-sized from three furnaces to two. The market prices the group largely on Saverglass sentiment. Cans, if valued as a standalone infrastructure-like asset, arguably accounts for a large share of the current enterprise value.

Revenue$1.4B
EmployeesN/A
Market CapN/A
Founded2013
Victoria, Australia
Orion

Orion Minerals Limited

Premium
Information Technology

Orion Minerals is an Australian-domiciled, dual-listed (ASX/JSE) base metals developer. It is trying to become South Africa's next significant copper producer by restarting two historic, fully permitted brownfield mining districts in the Northern Cape. Its flagship asset is the Prieska Copper Zinc Mine (PCZM), a top-30 global volcanogenic massive sulphide (VMS) deposit. Prieska historically produced about 430kt of copper and 1Mt of zinc. Its March 2025 Definitive Feasibility Study (DFS) supports a 13.2-year, 2.4Mtpa operation at a first-quartile all-in sustaining cost (AISC) of US$0.94/lb copper, net of zinc credits. The second hub is the Okiep Copper Project (Flat Mines), which is currently being optimised. Development funding rests on a binding US$250m Glencore prepayment and offtake facility, alongside the Industrial Development Corporation (IDC) as an equity partner and Triple Flag as an existing stream and credit holder. Orion's investment case is a call on copper scarcity combined with execution in a complex jurisdiction. Its main risks are financing close, construction delivery and dilution. --- **Company's own description (FY2026 Annual Report, paraphrased).** Orion describes itself as moving from explorer and developer to copper and base metals producer in the Northern Cape. Its stated purpose is to unlock resources through people to improve the world. It advances two fully permitted projects by revitalising legacy mines that retain significant exploration potential. Two Australian exploration projects provide longer-term optionality. **Independent characterisation.** Orion is a single-jurisdiction, pre-revenue mine developer with a staged plan: 1. **Prieska Uppers (Phase 1).** A small, high-grade underground operation in the near-surface crown pillar. It is accessed from an existing decline and processes about 240ktpa (20kt/month) through a Build-Own-Operate-Transfer (BOOT) concentrator supplied by ENPROTEC. The Uppers Probable Ore Reserve is 629kt at 2.3% Cu. The phase is planned to run for about 4.3 years and produce a bulk copper-zinc concentrate. First concentrate is targeted about 13 months after Glencore Tranche A funding closes. 2. **Prieska Deeps (Phase 2).** Dewatering of historic workings, refurbishment of the Hutchings Shaft and construction of a 2.4Mtpa plant. At steady state this produces separate copper and zinc concentrates of about 22ktpa Cu and 65ktpa Zn. 3. **Okiep Flat Mines.** A copper-only underground project (10Mt resource at 1.3% Cu). It is being optimised to reduce capital, with construction targeted from 2028. 4. **Exploration.** About 3,400km² of rights, covering roughly 70% of the exposed Areachap Belt and 75% of the exposed Okiep District, supported by the 2026 BHP Xplor accelerator. **Revenue model.** Orion's future revenue will come entirely from sales of physical products: base metal concentrates sold under offtake contracts. It has no service, subscription or licensing income. Glencore's prepayment is repaid through concentrate deliveries, so a large share of early cash flow is effectively pre-committed. The September 2025 term sheet referenced 100% offtake of zinc and copper concentrates for 5 to 10 years (Reuters, 17 Sep 2025). Reported "revenue" to date consists of interest and other income: A$0.32m in FY2026. **Value chain position.** Upstream mining and concentration only. Orion does not smelt or refine. Concentrates go to Glencore, a trader and smelter owner, under linked offtake agreements. **Customer types and end-markets.** In the near term there is one customer, Glencore. The ultimate end-markets are copper for power grids, renewable energy, electric vehicles, data centres, construction and industry, and zinc for galvanising steel used in infrastructure. **Ownership structure at asset level (FY2026 Annual Report).** The CFO review states that after the partial conversion of its ZAR344.5m loan, the IDC holds 23.8% of PCZM HoldCo, which equates to about 16.7% effective in Prieska, plus a ZAR272.4m shareholder loan claim. The BEE partner at Prieska is Prieska Resources (owned by Safika Resources, Black Star Minerals and Kolobe Nala Investment Company). At Okiep it is Landmark Capital Investments, led by Lulamile Xate.

RevenueN/A
Employees13
Market CapN/A
FoundedN/A
Victoria, Australia
OrionMetals

Orion Metals Limited

Premium
Information Technology

Orion Metals Limited is a Brisbane-based former junior mineral explorer that, at its last public disclosure, had become a cash shell controlled by Hong Kong-registered Excellence Holdings HK Ltd. Incorporated in 2001 as Queensland Gold and Minerals Limited and renamed in 2009, the company built a portfolio of rare earth element (REE), heavy rare earth, tin-tungsten and gold exploration projects. These were located in north Queensland (Top Camp, Mt Surprise), central Queensland (Mt Ramsay) and Western Australia (Tanami West). Chronic underfunding forced it to surrender, farm out and finally sell every project between 2019 and December 2021. Without assets, it was suspended by the ASX in June 2022 and removed from the Official List in June 2024. Its final disclosed strategy was to acquire a more advanced mining or exploration asset. It raised A$1.5 million in private placements in FY2024 to fund that search. The company has negative equity, no revenue and no disclosed operations. --- **Company's own description.** In its FY2020 Annual Report (year ended 29 February 2020), the company described its principal activity as exploration for rare earth elements, including heavy rare earth elements, and gold. It reported no significant change in the nature of those activities. By its H1 FY2024 Interim Report (half-year ended 31 August 2023), the description had changed. The company said its principal activity *had been* exploration for rare earth metals and gold. It explained that its remaining tenement interests were sold in December 2021 and that it was now looking to acquire new assets. **Independent characterisation.** At its last disclosure, Orion Metals was a pre-revenue, asset-less shell. Its business model had moved through three phases: 1. **Phase 1 – Project generator / explorer (circa 2007–2018).** The company held an early-stage portfolio across Queensland and Western Australia. Targets included REE and HREE (neodymium, gadolinium, europium, terbium, dysprosium, yttrium, lanthanum, cerium), tin-tungsten, IOCG copper-gold and alluvial gold. Value creation depended entirely on discovery, followed by sale, joint venture or development. 2. **Phase 2 – Retrenchment and divestment (2018–2021).** Funding constraints led to the following steps: - a farm-in with PVW Resources NL on Tanami West (February 2018), then its outright sale for A$250,000 (agreement August 2019); - surrender of Mt Surprise and Mt Ramsay tenure (FY2020); - sale of the Top Camp mining leases to Mayfair Corporations Group Pty Ltd for A$500,000 (agreement 13 July 2021, completed 15 December 2021). 3. **Phase 3 – Listed shell seeking a transaction (2022–2024).** The company retained advisers to identify more advanced or developed mining and exploration assets and to arrange capital raisings. It remained suspended throughout this phase and was delisted in June 2024. **Revenue model.** The company has never generated operating revenue. The audited five-year summary in the FY2020 Annual Report shows revenue of A$2,500 in FY2017 and nil in FY2016, FY2018, FY2019 and FY2020. Cash inflows have come from: - equity issues, mainly option exercises by EHHK and private placements; - tenement sale proceeds (Tanami West A$250,000; Top Camp A$500,000); - interest-free, unsecured loans from related parties (EHHK; Australia Cayenne Holdings Pty Ltd, a related entity of director Bin Cai; and Joanna Yan); - deferral of director fees (A$1,109,896 owed to directors at 31 August 2023); - a minor COVID-era ATO Cashflow Boost (A$15,288 in H1 FY2021).

RevenueN/A
EmployeesN/A
Market CapN/A
Founded2001
Fig Tree Pocket, Australia
Orcoda

Orcoda Limited

Premium
Information Technology

Orcoda Limited is a Queensland-headquartered micro-cap that describes itself as a software-led technology company built around two proprietary "360" platforms. Transport360 is an AI-enabled transport booking, scheduling, routing and dispatch SaaS used by community transport, healthcare transport and freight operators. Contractor360 (formerly the patented iCURO / Orcoda Workforce Logistics System) is a workforce mobilisation, travel, accommodation and compliance platform. Around these platforms sit two complementary businesses: **Future Fleet:** telematics, AI cameras and cold-chain monitoring. **TBG (Betta Group):** electrical, communications and infrastructure contracting in Central Queensland. The group generated A$16.6m of total income and A$6.2m of annual recurring revenue (ARR) in FY2026, but remains loss-making at the statutory level. Its investment case changed in mid-2026. A three-year, occupancy-based workforce logistics and facilities management contract with Wagner Corporation at Wellcamp, Toowoomba, is estimated at about A$8m per year. Management says it lifts entry FY2027 ARR to about A$14.2m. The case now turns on converting that reference win, and a rebuilt sales engine, into scalable software growth. --- ### The company's own description (FY2026 Annual Report) The FY2026 Annual Report opens with the line "Optimising People in Motion." It states that Orcoda addresses operational complexity for organisations running large workforces, vehicle fleets and logistics networks. Its operating system across the 360 solutions optimises how organisations deploy people, fleets and infrastructure to reduce cost, improve compliance and raise productivity. The Appendix 4E describes Orcoda as a leading provider of integrated smart technology solutions in transport logistics, workforce logistics and transport infrastructure. Its stated mission is to be clients' trusted partner in digital transformation, and its long-term vision is to be a leading Smart Cities transport technology solutions provider. The Directors' Report lists three principal activities: 1. Sale, implementation and support of transport software and fleet management solutions to transportation and healthcare transport providers. 2. Smart and traditional infrastructure, communications and electrical contracting services aligned to its "smart transport corridors" vision (road, rail and air). This activity also includes sale, implementation and support of the patented Contractor360 workforce software, combined with management expertise and/or contracting services, for infrastructure and resources companies. 3. Continuing R&D aimed at becoming a leading integrated Intelligent Transport Management System (ITMS) provider. ### Business model and revenue model | Revenue stream | Recognition basis | FY2026 (A$) | FY2025 (A$) | |---|---|---|---| | Services revenue (SaaS, fleet management subscriptions, contracting, workforce services) | Over time | 14,865,941 | 13,255,949 | | Hardware sales and installations (mainly Future Fleet telematics hardware) | Point in time | 1,309,327 | 3,272,735 | | Vehicle licensing income | Point in time / other | 2,400 | 34,400 | | Total revenue from contracts with customers | — | 16,177,668 | 16,563,084 | | Component | FY2026 estimate | Basis | |---|---|---| | Recurring software and subscription revenue | About A$6.2m of ARR (about 38% of revenue on a run-rate basis) | Company ARR disclosure | | Project and contracting revenue | About A$9.7m (about 60%) | Resource & Infrastructure segment external revenue | | Hardware | A$1.3m (8%) | Note 4 | AASB 15 disclosures (FY2026 Note 1 and Note 4) set out three revenue streams: The company classifies these streams as follows: **Project-based revenue:** (TBG contracting): recognised against contractual milestones. **SaaS:** recognised over the uninterrupted provision of access during the contract term. **Fleet management:** recognised over the contract term, measured by fleet units provided and days serviced. **Mix characterisation (analyst estimate from disclosed data):** These components overlap because ARR is a run-rate measure, not recognised revenue. Licensing is immaterial. From FY2027 the Wagner contract adds a large, occupancy-linked services stream. Management counts it in ARR. Economically, however, it is a facilities and workforce logistics service enabled by software rather than pure SaaS, a distinction also drawn by independent commentators (Stocks Down Under, June 2026). ### Value chain position Orcoda sits in two places in the value chain: **Application-software layer:** booking, optimisation, workforce mobilisation and compliance software. **Physical delivery layer:** telematics hardware installation, electrical/communications contracting, and (from July 2026) on-site workforce logistics and facilities management. The FY2026 Directors' Report presents this as a deliberate "total transport ecosystem." TBG's contracting capability is said to add value when bidding on projects because Orcoda can deliver both the digital layer and the physical infrastructure build. ### Customer types and end-markets | Area | Named customers / counterparties | |---|---| | Community / healthcare transport (Transport360) | Comlink Australia; six community transport providers from the ACTA trial (July 2025); Whittlesea Community Transport; Hinterland Community Services | | Enterprise logistics | Northline; Mini-Tankers / Refuelling Solutions | | Local government | Waipā District Council (New Zealand fleet management, June 2025) | | Mobility trial | Koala Cars (Orcoda Connect carpooling trial, September 2023) | | Workforce logistics | Wellcamp Accommodation Pty Ltd, a Wagner Corporation affiliate (Contractor360 / workforce logistics, from 1 July 2026) | | TBG contracting | Aurizon, Energy Queensland, MAAS Group Properties, Joy Global Australia ("Joy Globe" as printed in the Annual Report), Schwarz Excavation; panel positions with major Central Queensland customers; EPC Solutions agreement referenced in the October 2025 update | | Seasonal (ceased) | Mt Buller transport contract, which did not continue in FY2026 | The FY2026 Results Presentation lists six key markets: trucking and logistics; construction and infrastructure; healthcare; mining and resources; government; and utilities. Named customers and counterparties drawn from public disclosures: ### Independent characterisation Orcoda is best understood as a hybrid micro-cap. It contains a small but genuinely profitable vertical-SaaS franchise: Transport Technology segment EBITDA of A$1.89m at a 29.4% margin in FY2026. That franchise is attached to a lower-margin, cyclical, customer-concentrated electrical contractor (TBG), and since July 2026 also to a large services contract whose economics have not been disclosed. The group carries A$9.9m of goodwill from earlier acquisitions. It has accumulated losses of A$90.4m, a legacy of the SmartTrans era. Its balance sheet is thin: A$1.6m cash at 30 June 2026 and a small net current liability. The equity story rests on three propositions: 1. The Wagner contract proves Contractor360 at scale. 2. A rebuilt, process-driven sales function under a new CEO can take Transport360 from about 40 to more than 100 customers (CEO's FY2026 letter). 3. Group operating leverage will turn the statutory loss into profit.

Revenue$0.0B
EmployeesN/A
Market CapN/A
Founded1983
Queensland, Australia
Optiscan

Optiscan Imaging Limited

Premium
Information Technology

Optiscan Imaging is a Melbourne-based, micro-cap medical technology company that designs and manufactures miniaturised confocal laser endomicroscopes — handheld and probe-based microscopes that image living tissue at single-cell resolution in real time, without physically removing and processing a biopsy. After roughly three decades as a component and OEM supplier (most notably as the imaging engine inside Carl Zeiss Meditec's CONVIVO neurosurgical system and, historically, Pentax's ISC-1000 GI endomicroscope), the company has pivoted under CEO Dr Camile Farah toward its own branded clinical devices: InVue (precision surgery), InForm (digital pathology) and InSpecta (veterinary). FY2026 marked the transition to a clinical-stage device company: InSpecta was launched commercially in the US veterinary market in July 2026, and FDA 510(k) submissions were lodged for InForm (1 October 2026) and InVue (5 October 2026). Revenue remains negligible (A$0.45M in FY2026); value hinges on regulatory clearance and commercial adoption. --- **Company's own description.** The FY2026 Annual Report describes Optiscan as a global leader in developing, manufacturing and commercialising imaging technologies for medical, translational and pre-clinical applications, whose technology enables real-time, non-destructive, three-dimensional, in-vivo digital imaging at the single-cell level and links surgery with pathology. The Directors' Report defines the principal activity as the development, manufacture and commercialisation of proprietary confocal imaging devices and digital solutions for surgical, pathology and veterinary applications, advanced through product development, clinical studies, regulatory activities, strategic collaborations and commercialisation in Australia, the United States and other markets (FY2026 AR, Directors' Report). **What the technology does.** Optiscan's core intellectual property is a miniaturised fibre-optic confocal scanning microscope. A probe is placed in direct contact with tissue (typically after a fluorescent contrast agent such as fluorescein is applied), and a laser scans an optical section beneath the tissue surface, generating microscopic images that resemble histology in seconds. The company's marketing materials contrast this with conventional pathology workflows (tissue excision, fixation, sectioning, staining, review), which can take hours to days. The intended clinical value propositions are: (i) intraoperative margin assessment — helping surgeons determine whether cancerous tissue remains at the resection margin, potentially reducing re-operations; (ii) rapid ex vivo digital pathology — imaging fresh excised specimens without frozen-section processing; (iii) telepathology — streaming images to remote pathologists; and (iv) AI-assisted detection of cancerous and precancerous tissue. **Business model and revenue model.** Historically Optiscan earned revenue from three sources: (a) OEM supply of imaging components and systems to Carl Zeiss Meditec (CZM) for the ZEISS CONVIVO neurosurgical endomicroscope; (b) sales of its research-grade ViewnVivo (formerly FIVE2) pre-clinical/translational imaging system to research institutions; and (c) services (repairs, out-of-warranty servicing) and system rentals. In FY2026, statutory revenue of A$448,769 comprised A$347,377 of goods sold and A$101,392 of services (FY2026 AR, Note 5). The intended future model is a hardware-plus-consumables-plus-software ("razor/razor-blade plus SaaS") model: capital sales of InVue, InForm and InSpecta systems, recurring sales of sterile disposable sheaths/drapes, and a cloud-based telepathology platform that management describes as a scalable recurring software revenue opportunity (FY2026 AR, pipeline table). Licensing is not currently a material revenue line. Non-operating income is economically more important than revenue today: FY2026 "other income" of A$3.71M comprised the Australian R&D Tax Incentive (A$2.40M, a refundable 43.5% offset for companies with turnover under A$20M), Cooperative Research Centres Projects (CRC-P) grant income (A$0.77M), and interest income (A$0.55M) (FY2026 AR, Note 6). **Value chain position.** Optiscan is vertically integrated across design, engineering, software, manufacturing/assembly (Mulgrave), quality systems and clinical research. It relies on external suppliers (several overseas) for key components (FY2026 AR, risk statement). Historically it sat upstream as an OEM component supplier to large device makers; it is now moving downstream to sell branded systems directly and via distributors. The company notes that the "vast majority" of its sales have been through distribution networks with formal agreements including minimum purchase requirements (FY2026 AR, distribution network risk). **Customer types and end-markets.** **Independent characterisation.** Optiscan is best understood as a long-duration, pre-commercial platform technology company with a small legacy OEM revenue stream that is now in decline. Its most important asset is a mature, miniaturised confocal hardware platform proven in a regulated OEM product (CONVIVO), giving it manufacturing and quality-system credibility unusual for a company of its size. The strategic pivot since 2021 has been to monetise that platform in its own name across multiple indications simultaneously. The risk profile is binary-leaning: FY2027 outcomes on the two pending 510(k) submissions and early InSpecta sales traction will largely determine whether the company becomes a revenue-generating device business or continues to rely on equity raises and R&D tax refunds.

Revenue$0.0B
EmployeesN/A
Market CapN/A
Founded1994
Victoria, Australia
oOh!media

oOh!media Limited

Premium
Information Technology

oOh!media is the largest Out of Home (OOH) advertising company in Australia and New Zealand. It held about 35% of the ANZ OOH market in CY25 and 36% of the Australian market on a rolling 12-month basis to 30 June 2026. Its network spans more than 30,000 digital and classic assets, including roadside billboards, street furniture, rail, retail centres, airports, office towers and universities. The company says this network reaches 98% of metropolitan Australians each week. oOh! monetises long-term concession and lease rights granted by governments, transport authorities, landlords and councils. It sells audiences to advertisers and agencies across its formats, increasingly through digital and programmatic channels. The structural case is that OOH has been the fastest-growing major medium in Australia, reaching a record 16.9% of agency media spend in the 12 months to June 2026. That case attracted a competitive private-equity contest. I Squared Capital, a global infrastructure investor, won it by valuing oOh! as "media infrastructure" at A$1.04bn EV. --- ### The company's own description oOh!media's standard boilerplate, repeated in every ASX release in 2025–2026, describes it as a leading Out of Home media company that enhances public spaces by creating engaging environments. Those environments help advertisers, landlords, leaseholders, community organisations, local councils and governments reach large and diverse public audiences. The network covers roadsides, retail centres, airports, train stations, bus stops, office towers and universities across Australia and New Zealand. The Annual Report 2025 adds that data and audience analytics let clients maximise media spend through accurate audience targeting. ### Business model oOh! sits between two groups. On one side are site owners: state transport agencies, toll-road operators, councils, shopping-centre owners, airport operators, office landlords and universities. On the other side are advertisers and their media agencies. **Supply side (cost base):** oOh! secures exclusive advertising rights through concession contracts, typically won in competitive tenders lasting from several years to more than a decade. It also secures leases on private land for billboards. Site-owner remuneration ("rent") comes in two forms. Fixed rent is a guaranteed minimum, often escalating. Variable rent is a revenue share. The mix drives gross margin. Management cited higher fixed rent and revenue mix for the 1.3 ppt margin decline in 1H25, and fixed-rent investment ahead of revenue for the 4.3 ppt decline in 1H26. Office and City & Youth contracts operate largely on variable rent (CY24 results). **Capital intensity:** oOh! funds the digitisation and construction of assets: large-format digital billboards, digital panels in rail stations and shopping centres, and bus shelters. Annual capex guidance has run at A$40–65M (CY24 A$45–55M; CY25 initially A$45–55M, revised to A$53–63M; CY26 initially A$55–65M, revised to A$40–50M in August 2026). **Demand side (revenue):** Revenue is mainly media revenue: advertising space and time sold by campaign, by audience package, programmatically, or through direct and agency deals. Non-media revenue includes contracted infrastructure revenue (for example, street-furniture-related services historically bundled into council contracts) and production and printing through Cactus Imaging. Digital made up 75% of media revenue in CY24, and programmatic revenue grew 94% year on year in CY24 (Appendix 4E CY24 commentary). ### Revenue model mix | Revenue type | Description | Disclosure | |---|---|---| | Media advertising, digital | Time-based sale of slots on digital screens (large-format, panels, rail, retail, airport, office) | 75% of media revenue in CY24 (CY24 annual report). | | Media advertising, classic/static | Printed posters and billboards sold by site and period | Remainder of media revenue (about 25% in CY24) | | Programmatic | Automated audience-based buying through demand-side platforms | Grew 94% in CY24. Absolute value not publicly disclosed | | Non-media / contracted revenue | Infrastructure and service revenue tied to some council and transport contracts | Declined in CY24 after a major street furniture contract was recontracted for lower rent (1H24 release) | | Production / printing (Cactus Imaging) | Large-format printing for OOH and other customers | Within "Other" (about A$19.7M in CY25, derived) | | Retail media (reo) | Turnkey in-store retail media network management for retailers | Exited 30 June 2026. The Petbarn offering moved to an in-house model | There is no subscription or licensing revenue of significance. The model is essentially advertising sales on top of a portfolio of long-dated, tendered rights. That is the feature that drew infrastructure investors. ### Value chain position oOh! is a vertically integrated media owner and operator. It handles site acquisition and tendering, asset build and maintenance, content operations, audience measurement (through the industry MOVE system run by the Outdoor Media Association), sales and trading, and (through Cactus) production. It is not a media agency, though it trades heavily through agencies. Agency media spend, as measured by the Standard Media Index (SMI), is the key demand barometer. ### Customer types and end-markets **Advertisers:** National brand advertisers across automotive, communications/telco, FMCG, retail, finance, government, travel, and media and entertainment. Management named Automotive, Communications and FMCG as leading the Q3 2026 recovery. **Agencies:** Holding-company and independent media agencies (most revenue is agency-booked). **Site partners (the B2B "customers" of the concession model):** Transport for NSW and Sydney Metro, Victoria's Department of Transport and Planning, Cross Yarra Partnership (Melbourne Metro Tunnel), Transurban, EastLink, councils (Woollahra, Waverley and others), shopping-centre owners, airports (including Melbourne Airport), office landlords and universities. **Geographies:** Australia (the large majority of revenue) and New Zealand. ### Independent characterisation oOh! combines a long-duration infrastructure asset (exclusive concessions over high-footfall public spaces) with cyclical, brand-driven ad spend. Its operating leverage is high because a large share of costs (fixed rent and opex of about A$155–161M) does not flex with revenue. That explains why a 1% revenue increase in 1H26 still produced a 23% fall in adjusted underlying EBITDA. Long-run growth is structural (OOH share gains from TV and radio, and digitisation lifting yield per site). Contract churn is the dominant idiosyncratic risk. Losses of Sydney Trains (2021), City of Sydney (to QMS), Vicinity (2024) and Auckland Transport (2025) have repeatedly offset wins such as Sydney Metro, Metro Tunnel and Transurban.

Revenue$0.4B
EmployeesN/A
Market CapN/A
Founded1989
North Sydney, Australia
OliveX

OliveX Holdings Ltd

Premium
Information Technology

OliveX Holdings is a micro-cap, Hong Kong-operated, Australian-incorporated digital fitness company that sought to sit at the intersection of fitness, mobile gaming and blockchain. Spun out of the Animoca Brands ecosystem in 2020, it built its strategy around a "fitness metaverse" in which real-world exercise earns NFTs and its ERC-20 utility token, DOSE. Its most valuable asset was acquired rather than built: UK studio Six to Start, maker of the audio running game Zombies, Run!, bought in 2021 for roughly US$7.9m of accounted consideration. Its own Web3 titles, Dustland Runner and Dustland Rider, launched in 2022 into a collapsing crypto market. Revenue never exceeded an estimated A$3m per year while losses ran several times revenue. After delisting from the NSX in 2023 the company progressively shrank, laid off almost all Six to Start staff in 2025, and sold Zombies, Run! back to its co-creator in November 2025. It is now a residual, opaque, private-like entity. --- ### Company's own description In its FY2021 Annual Report the company described its principal activities as being a technology company that aims to improve the health and fitness of users through gamification, coaching and artificial intelligence, with technology products developed in-house. By the December 2022 half-year report, the description had shifted to a digital fitness company providing applications, smart technology and fitness gamification leveraging blockchain and move-to-earn functionality, positioned across the fitness and wellness industry, the gaming industry and the blockchain/NFT market (Source: Interim Report H1 FY2023, Directors' Report 5.1). The December 2022 media release described the OliveX fitness metaverse as connecting consumers exercising at home, in the gym or outdoors with brands, influencers and coaches in over 170 countries, underpinned by the DOSE token (Source: Media Release, 21 December 2022). ### Independent characterisation OliveX operated as a small consumer software publisher with three overlapping revenue engines, each of which proved sub-scale: 1. **Subscription mobile games (Web2).** Zombies, Run! and later the ZRX app (Zombies, Run! plus Marvel Move) generated the bulk of revenue through in-app subscriptions. At acquisition, Zombies, Run! claimed ~300,000 monthly active users and ~50,000 paying subscribers with average revenue per paying subscriber above £25 per year (Fieldfisher, March 2021; PocketGamer.biz quoting Rumjahn). 2. **Web3 move-to-earn games and digital assets.** Dustland Runner (running) and Dustland Rider (indoor cycling) rewarded exercise with DOSE tokens and NFTs. Monetisation came through NFT sales (e.g., the Genesis NFT auction, February 2023: 370 NFTs for 1,850 ETH, ~US$3.1m at the time) and DOSE token sales, the proceeds of which were accounted for as a liability ("DOSE token payable") rather than revenue until in-game utility obligations were satisfied. 3. **Hardware and B2B services (legacy, largely exited).** The KARA Smart Fitness Mirror sold through Hong Kong retail partners and the Volution gym-management software platform (UK), closed in 2022. ### Revenue model mix (latest disclosed: H1 FY2023, six months to 31 December 2022) | Revenue line (A$) | H1 FY2023 | % of total | |---|---|---| | Apps and games | 907,205 | 91.4% | | Mirror sales | 71,153 | 7.2% | | Services | 13,949 | 1.4% | | Development services | 0 | 0.0% | | Total | 992,307 | 100.0% | Source: Interim Report H1 FY2023, Note 3. The mix is effectively a single-product subscription business (Zombies, Run!) with marginal hardware sales. NFT sales of ~A$3.1m were reported for calendar 2023 to early June (Notice of General Meeting, 2 June 2023), which would have made FY2023 the company's highest-revenue year, but audited FY2023 figures are not publicly available. ### Value chain position and customers OliveX was a content developer/publisher distributing via Apple App Store and Google Play (Web2) and Polygon/Ethereum blockchain infrastructure (Web3). It licensed third-party IP (Marvel) and relied on platform intermediaries for distribution and payments. Customer types: individual consumers (runners, cyclists), crypto/NFT collectors, and, historically, gyms and fitness brands via Volution (Les Mills, Gold's Gym referenced in FY2021 Annual Report) and retail resellers for KARA mirrors (Fortress, HKTVMall, Hong Kong Broadband). End-markets: consumer digital fitness, mobile gaming, Web3/NFT gaming.

Revenue$0.0B
EmployeesN/A
Market CapN/A
Founded2017
Perth, Australia
Global

Global Uranium and Enrichment Limited

Premium
Information Technology

Global Uranium and Enrichment Limited, the former Okapi Resources, evolved from a DRC- and Kimberley-focused gold explorer into a North American uranium development company with a distinctive foothold in enrichment technology. Its asset base centres on the Tallahassee Uranium Project in Colorado, with a JORC 2012 Mineral Resource of 52.2 Mlb U3O8 at 530 ppm, supported by a May 2025 Scoping Study on the Hansen deposit. It also held a 50% interest in the Pine Ridge ISR project in Wyoming's Powder River Basin, the Maybell and Rattler projects in Colorado and Utah, six Athabasca Basin claims in Saskatchewan, and a 21.9% stake in Ubaryon Pty Ltd, a private Australian enrichment technology developer. Chronically under-capitalised relative to its resource base, GUE was acquired in February 2026 by its Pine Ridge JV partner and 19.7% shareholder, Snow Lake Resources (now Frontier Nuclear), becoming the core uranium asset vehicle inside a Nasdaq-listed U.S. nuclear fuel cycle platform. --- **What the company does.** GUE was a mineral exploration and early-stage development company. It acquired, explored, and advanced uranium projects in the United States and Canada, held a minority strategic investment in an enrichment technology company, and retained residual gold and base-metal interests in Australia. Market Index's issuer description summarises the business as uranium exploration in North America plus gold exploration in Australia, with the near-term aim of discovering and developing uranium deposits in North America (Market Index, GUE profile). **Company's own description.** In its takeover-era disclosures, GUE described itself as an Australian listed company offering exposure both to uranium exploration and development and to the enrichment space, building a portfolio of advanced, high-grade uranium assets in prolific U.S. and Canadian districts while holding a cornerstone position in Ubaryon (GUE "About" boilerplate reproduced in Snow Lake release, 6 Oct 2025). The FY2023 annual report framed the growth strategy as aiming to be a leader in North American carbon-free nuclear energy supply (FY2023 Annual Report, 29 Sep 2023). **Business model.** GUE had no operating revenue. Its model was the classic junior-resource value-creation model: acquire under-valued historic deposits cheaply (Tallahassee, Hansen, Maybell were all historically drilled or produced in the 1970s–80s), convert historic data into JORC-compliant resources, advance through permitting and technical studies, and monetise via development, joint venture, or corporate transaction. The eventual outcome was the last of these: a scheme-of-arrangement takeover by a Nasdaq-listed partner. **Revenue model mix.** **Value chain position.** Upstream: exploration and pre-development of uranium (front end of the nuclear fuel cycle, mining/milling stage), with an indirect minority exposure to the conversion/enrichment stage via Ubaryon. GUE's Hansen development concept relied on contract toll milling of upgraded ore at a third-party mill rather than owning processing infrastructure (Scoping Study, 6 May 2025). **Customer types and end-markets.** Prospective customers for any future U3O8 production would be nuclear utilities and fuel buyers; U.S. utilities and government strategic reserve buyers are the logical domestic market given policy emphasis on domestic supply. No offtake agreements were disclosed. **Independent characterisation.** GUE was best understood as a resource-rich, cash-poor U.S. uranium aggregator. By 2025 it controlled one of the larger undeveloped JORC uranium resources held by an ASX junior in the U.S., yet traded at a fraction of book value (price-to-book c. 0.59–0.65 per FNArena and Google Finance) because it lacked the balance sheet to advance development and its flagship economic interest at Hansen was 51% rather than 100%. The enrichment stake gave it narrative differentiation but no cash flow. The Snow Lake JV and takeover solved the funding problem at the cost of independence.

RevenueN/A
EmployeesN/A
Market Cap$0.0B
Founded2017
West Perth, Australia
Oakridge

Oakridge International Limited

Premium
Information Technology

Oakridge International is an Australian micro-cap healthcare-technology company. In practice it is the listed holding company for JCT Healthcare Pty Ltd, an Adelaide-based designer, supplier, installer and maintainer of IP nurse call systems, assistive technology, real-time location systems (RTLS) and related software. JCT has operated for more than two decades. Its customers are hospitals, residential aged care, disability care, dementia care and supported independent living (SIL) providers, mainly in Australia. The listed entity has had several lives: a geothermal developer in Indonesia and India, then an IoT platform company (Xped), then a consolidated healthcare-technology business. In FY2026 it recorded revenue and other income of $3.45 million and its first statutory profit since FY2021 ($109,171). However, that profit depends on R&D tax incentives. With a market value near A$2 million, majority control by its CEO and a three-person board, Oakridge is an illiquid, founder-style turnaround story in a market where well-capitalised consolidators are active. --- ### The company's own description The FY2026 Annual Financial Report says the Group sells professional healthcare-technology equipment and solutions to healthcare facilities. It develops and distributes its own range of nurse call hardware and software for hospitals, aged care, disability care and supported independent living. The report says the Group continues to expand into assisted independent living technologies, using synergies with its legacy Internet of Things (IoT) platform. It also says the Group is looking at other emerging technology businesses focused on IoT and healthcare. The FY2026 report adds two items: - Strategic planning on enterprise-grade reporting and AI-enabled capabilities for the NuCaMS platform. - Evaluation of a broader "connected clinical care" offering. This would combine nurse call workflow data with complementary consumables and non-invasive monitoring inputs, to support a more proactive model of care. The company describes this opportunity as early-stage and subject to evaluation and approvals. The language on adjacent sectors has changed over time. The FY2024 report listed renewable energy, energy storage, new-energy vehicles and energy-saving materials as exploratory interests. By FY2026 the stated adjacencies had narrowed to IoT, healthcare and AI-related care technology. This is a meaningful sharpening of focus. ### Independent characterisation | Revenue type (A$) | FY2023 | FY2024 | FY2025 | FY2026 | |---|---|---|---|---| | Sale of goods, point in time (A$) | 883160 | 661028 | 2004339 | 2908722 | | Projects and services, over time (A$) | 214572 | 153704 | 225908 | 185698 | | Total revenue from contracts with customers (A$) | 1097732 | 814732 | 2230247 | 3094420 | | Goods share of customer revenue (%) | 80.5 | 81.1 | 89.9 | 94.0 | Oakridge is, in substance, a single-business company. All of its revenue from customers comes from the Healthcare Technology segment (JCT Healthcare Pty Ltd) and all of it is earned in Australia (FY2026 Annual Financial Report, Notes 4 and 5). The other reported segments are dormant or legacy: **Technology development:** is the former Xped IoT/ADRC platform. It had no revenue and only $55,000 of consulting cost in FY2026. **Geothermal projects:** comprises fully impaired Indonesian and Indian interests. Its only economic value is a contingent earn-out from KS Orka Renewables on the Sokoria project. **Unallocated:** captures listed-company overheads. **Business model.** JCT is a project-based systems integrator with its own product IP. It designs and specifies proprietary nurse call hardware (call points, pendants, annunciator displays, intercoms) and software (the NuCaMS platform, mobile apps, reporting and integrations). It procures and holds inventory, then delivers projects through programming, first-fix, component delivery, commissioning and installation. It also provides recurring 24/7 technical support, maintenance, networking and software development services. It sells directly and through a national network of channel partners (installers and integrators), which management has been actively expanding. **Revenue model mix.** Revenue is overwhelmingly product-led and recognised at a point in time: Source: FY2024 and FY2026 Annual Financial Reports, Note 5. The share row is an analyst calculation. Subscription and licensing revenue are not separately reported. The legacy Bio SA royalty-linked messaging licence produced no royalties in FY2024–FY2026. The trend is notable: as revenue has scaled, the mix has moved further toward hardware. Services and projects fell to 6.0% of customer revenue in FY2026. This contrasts with listed peer Austco Healthcare, which is building a recurring software and maintenance layer (12% of its FY2026 revenue, per Austco's FY2026 results). **Value-chain position.** JCT sits in the middle of the value chain. It owns product design and software IP and outsources component manufacturing. The FY2026 report refers to RTLS hardware moving into production and to "inventory in transit", implying imported components. It also handles installation, either directly or through partners. It does not own contract-manufacturing capacity. **Customer types and end-markets.** - Public and private hospitals (acute care). - Residential aged care operators. - Disability care providers and SIL accommodation, including NDIS-funded participants and occupational-therapist-specified assistive technology. - Dementia care units. - Retirement and independent living villages. Customers are typically facility operators, procuring directly or through builders and electrical integrators. No individual customer concentration data is disclosed.

RevenueN/A
EmployeesN/A
Market CapN/A
Founded2006
Adelaide, Australia
Oakajee

Oakajee Corporation Limited

Premium
Information Technology

Oakajee Corporation Limited is a Perth-based, ASX-listed micro-cap gold explorer whose operating asset is the Paynes Find Gold Project in Western Australia's Murchison region, roughly 455km by road north-east of Perth, where it holds an 80% interest (and manages an unincorporated joint venture) over a package of exploration and mining tenements plus one wholly owned licence. The company is pre-resource and pre-revenue: it has no JORC Mineral Resource, no production and only nominal interest income. Its economic substance is, in practice, a hybrid of an early-stage exploration programme and a small listed-equity portfolio — chiefly 11 million shares in Santa Fe Minerals (ASX: SFM), a related company chaired by Oakajee's Managing Director, and 1.6 million shares in Turaco Gold (ASX: TCG). At 30 June 2026 these holdings were valued at A$3.4 million, approximately equal to Oakajee's entire market capitalisation, implying the market ascribes little or no value to the Paynes Find exploration ground. The near-term investment case rests on follow-up drilling of a new gold-bearing shear zone discovered in late 2025. --- ### Company's own description In its statutory segment note, Oakajee describes a single reportable segment comprising "mineral exploration in Australia and investing in mineral exploration companies in Australia" (FY2022 Annual Report, Note 18). Its quarterly reports describe the core activity as "regional exploration of its Paynes Find project in Western Australia", and state that the company "continues to assess other potential gold exploration projects" (Dec 2025 quarterly report). Morningstar's business description, derived from company filings, characterises Oakajee as engaged in investment in the resources sector and exploration for gold and base metals within Australia. ### Independent characterisation Oakajee is best understood as a closely held, low-overhead exploration shell with three components: 1. **Exploration asset (Paynes Find Gold Project, WA).** An 80% joint-venture interest in four granted tenements and 100% of a fifth, prospective for gold (and, historically, base metals). Exploration to date has been grassroots: soil geochemistry, rock-chip sampling, auger, and shallow aircore (AC) drilling under lake-clay and gravel cover. The best result reported in the last 18 months is 5m at 925ppb Au (0.925 g/t Au) in hole PFAC122, defining a new NNW-trending sheared-basalt zone with an interpreted 2km target strike (19 Jan 2026 ASX announcement). 2. **Listed-equity portfolio.** Holdings in ASX-listed resource companies designated at fair value through other comprehensive income (FVOCI). At 31 Dec 2025 the portfolio comprised 11,000,000 SFM shares and 1,600,000 TCG shares worth A$4.691m; at 30 Jun 2026 the portfolio was valued at A$3.400m (Dec 2025 and Jun 2026 quarterly reports). The portfolio is the company's principal source of liquidity and has been periodically monetised to fund operations (A$198k of disposal proceeds in H1 FY2026 per Appendix 5B). 3. **Corporate overhead.** Annual cash burn of roughly A$0.4–0.6m, dominated by director fees, administration and modest exploration spending. ### Business and revenue model | Revenue model component | Share of revenue | Comment | |---|---|---| | Product sales | 0% | No production; no mineral sales | | Services | 0% | None | | Subscription / licensing | 0% | None | | Interest income | ~100% of "revenue and other income" | A$3,909 in FY2026 (Quartr summary of FY2026 annual report) | | Dividend income | Not disclosed / nil | Investee companies are themselves explorers/developers | | Government grants | Occasional | A$7,857 in FY2021 (COVID-era support) (FY2022 Annual Report) | The value-creation model is the standard junior-explorer model: spend shareholder capital on drilling to make a discovery, then monetise via resource definition and sale/joint venture, or via share-price re-rating enabling equity raises. A secondary model is capital gains on strategic listed holdings, which are recognised through other comprehensive income and never recycled to profit or loss under the company's AASB 9 election. ### Value-chain position, customers and end-markets Oakajee sits at the very front of the mining value chain (greenfields/brownfields exploration). It has no customers. Its eventual "end-market" would be the gold market — either via sale of a deposit to a producer (Murchison producers such as Ramelius Resources operate in the broader region; Oakajee itself has cited Ramelius's Penny mine as a geological analogue for its Paynes Find North target) or, theoretically, via toll treatment. The lithium rights over two tenements belong to the registered holder (Sayona Lithium Pty Ltd), not Oakajee.

RevenueN/A
EmployeesN/A
Market CapN/A
Founded2006
Nedlands, Australia
Nyrada

Nyrada Inc.

Premium
Information Technology

Nyrada is a single-asset, clinical-stage Australian biotechnology company, incorporated in Delaware. Its platform is the inhibition of Transient Receptor Potential Canonical (TRPC) 3/6/7 ion channels. Its lead molecule, Xolatryp®, is a first-in-class intravenous small molecule designed to limit pathological calcium influx into cells exposed to ischaemic or toxic stress. Xolatryp completed a 48-subject Phase I trial in healthy volunteers in 2025 with no serious adverse events. In July 2026 it entered PROTECT-MI, a 100-patient, randomised, placebo-controlled Phase IIa trial in STEMI heart-attack patients undergoing primary PCI. No approved therapy exists for myocardial ischaemia-reperfusion injury. Preclinical data also support use in ischaemic stroke, traumatic brain injury and anthracycline (doxorubicin) cardiotoxicity, plus possible anti-tumour additivity. Nyrada has no product revenue and funds itself through equity and Australia's refundable R&D tax incentive. A A$12m placement in September 2026 is intended to fund PROTECT-MI to topline data, expected in 2H CY2027. --- ### Company's own description Nyrada describes itself as a clinical-stage biotechnology company focused on discovering and developing innovative small-molecule therapies that target TRPC ion channels. It states that its lead candidate, Xolatryp®, has shown efficacy in preclinical cardioprotection, neuroprotection and oncology models, has completed a first-in-human Phase I trial, and is now in a Phase IIa trial assessing safety and preliminary efficacy in reducing cardiac reperfusion injury in STEMI patients undergoing PCI (FY2026 Full Year Results, 18 Aug 2026). The FY2023 Annual Report gave the strategic framing that still applies. The vision was to become a high-growth pharmaceutical discovery and development company specialising in early-stage development of novel treatments. The strategy was to target diseases with unmet clinical need or suboptimal current treatments, and to monetise them by advancing highly optimised drug candidates. ### Independent characterisation Nyrada is a pre-revenue, single-mechanism, single-lead-asset drug developer. Its business model is "develop-to-partner." At IPO in 2020, CEO James Bonnar described the plan as taking drug candidates up to about Phase IIa and then selling or licensing them (Small Caps, Feb 2020). The FY2026 materials and the September 2026 raise are consistent with that plan: they prioritise a clean Phase IIa readout, a US FDA IND, a commercial dose form, and a follow-on oral TRPC inhibitor. These are the assets a pharmaceutical licensee would want to see. ### Revenue model | Revenue type | Status | Comment | |---|---|---| | Product sales | None | No approved products | | Services | None | — | | Subscription | None | — | | Licensing / milestones | None to date | Intended future model: out-license or sale after Phase IIa | | "Other income" | Recurring | Mainly the Australian refundable R&D tax incentive, plus interest income. Reported "revenue" of A$2.56m in FY2025 was of this nature. | ### Value-chain position Nyrada covers discovery and preclinical pharmacology through early clinical development (Phase I–IIa). Medicinal chemistry, GLP toxicology, drug manufacturing (CMC), clinical operations and preclinical efficacy studies are outsourced to contract research and manufacturing organisations and academic collaborators. The specific CROs and CDMOs are not publicly named in the sources reviewed. Commercial manufacturing, late-stage trials and commercialisation would fall to a future partner. ### Customer types and end-markets There are no current customers. The prospective customers are large and mid-cap pharmaceutical companies with interests in acute cardiology, cardio-oncology, critical care or neurology. Ultimately, the drug would be prescribed in hospitals: - Interventional cardiology: STEMI patients undergoing primary PCI - Cardio-oncology: patients receiving anthracycline chemotherapy such as doxorubicin - Acute neurology: ischaemic stroke and traumatic brain injury - Possible extension to oncology combination therapy (preclinical anti-tumour additivity with doxorubicin)

RevenueN/A
EmployeesN/A
Market CapN/A
Founded2017
Sydney, Australia
Nusantara

Nusantara Resources Limited

Premium
Information Technology

Nusantara Resources was created in 2017 to take one asset, the Awak Mas gold deposit in South Sulawesi, out of the unlisted One Asia Resources and into a public vehicle that could fund it to production. Over four listed years it ran feasibility work that turned a 1.74 Moz resource into a 1.1 Moz, and later 1.53 Moz, reserve base. It also brought in Indonesian conglomerate Indika Energy as strategic partner. The junior's core problem was financing roughly US$150m+ of capex for a foreign-jurisdiction project from a small market capitalisation. That problem ended in a 2021 cash takeover by Indika. Today Nusantara is an intermediate holding company in Indika's diversification away from thermal coal. Its subsidiary Masmindo is about 61% through construction of a 100 koz/yr open-pit carbon-in-leach (CIL) mine. Trial production is targeted for December 2026 and first gold pour for Q1 2027. --- **What the company does.** Nusantara is a single-asset gold development holding company. Its value lies entirely in its ownership of PT Masmindo Dwi Area, which holds the Awak Mas Contract of Work over a 14,390-hectare concession in Luwu Regency, South Sulawesi. About 1,444 hectares of the concession are ready for development, and the concession contains three deposits: Awak Mas, Tarra and Salu Bulo (Indika public expose, 27 Nov 2025). **Company's own description (last listed period).** In its final ASX announcements, Nusantara called itself an ASX-listed gold development company whose flagship was the Awak Mas Gold Project in South Sulawesi (ASX announcement, 6 Oct 2021). At its 2017 IPO, the managing director described a broader ambition: a gold explorer, developer and operator focused on the Asia-Pacific (FNN interview, 13 Jul 2017). **Independent characterisation.** Nusantara is now a pass-through holding vehicle with no operations of its own. The economic engine is Masmindo, which is building an open-pit mine with a CIL processing plant. The plant was designed at 2.5 Mtpa in the 2018 DFS, and an expansion case of 3.9 Mtpa was studied in 2020. Planned output is about 100,000 oz of gold per year at an average grade of around 1.37 g/t (Indika public expose, Nov 2025). **Business and revenue model.** **Group context.** Inside Indika Energy, Awak Mas is the lead project in the "minerals" leg of the parent's plan to diversify away from coal. Indika has said the gold business will become one of its two largest businesses by scale (Kontan, 20 Nov 2024). In H1 2026, 99.1% of Indika's US$83.1m capex went to non-coal businesses, and Awak Mas took US$71.4m of that (Warta Ekonomi / KabarBursa, Aug 2026).

RevenueN/A
EmployeesN/A
Market CapN/A
Founded2017
South Melbourne, Australia
Novatti

Novatti Group Limited

Premium
Information Technology

Novatti Group is a Melbourne-based, ASX-listed micro-cap payments infrastructure company that describes itself as a payments leader bridging traditional payments and regulated digital finance. After a decade of acquisitive, multi-country expansion that included a restricted bank (International Bank of Australia), a stake in Reckon, Malaysian bill-payment operator ATX and a subscription-billing business (Emersion), the group has spent FY24–FY26 under CEO Mark Healy dismantling non-core assets and exiting low-margin revenue. What remains is a focused Australia/New Zealand franchise in card issuing (Visa prepaid and debit, BIN sponsorship for fintechs), merchant acquiring (Visa/Mastercard principal licences, Alipay/WeChat Pay acceptance) and Asia-to-Australia wallet bill payments, plus an equity-accounted minority stake in AUDC Pty Ltd, issuer of the AUDD stablecoin. FY26 delivered the group's first positive reported EBITDA (A$2.0m, flattered by a deconsolidation gain) on revenue of A$29.9m at a 51% gross margin. The investment case is a turnaround-plus-option story constrained by a thin balance sheet. --- ### Company's own description In its FY25 Annual Report the company describes itself as a leading Australian payments company, established in 1995, that provides a single destination for all payment needs, serving customers from fintechs to corporates through tailored online, in-person, international and card solutions. The FY25 Directors' Report states its principal activity as a payments fintech that enables businesses to "pay and be paid". By the FY26 Appendix 4E (31 August 2026), the self-description had evolved to a payments leader bridging traditional payments and regulated digital finance, with an articulated vision of integrated payments infrastructure and a single regulated bridge across all forms of money. ### Business model and revenue model | Revenue line | Revenue model (as disclosed) | Character | |---|---|---| | Acquiring | Transactional, integration and monthly fees charged to merchants; set-up fees recognised when service provided | Transaction + recurring | | Issuing | Monthly program fees plus transaction fees for prepaid and debit Visa cards issued under Visa licence; set-up fees | Recurring + transaction | | Cross Border (B2B) | Fees for cross-border payments and global currency accounts / FX; wholesale cross-border exited Q4 FY25 | Transaction | | Novatti Billpay / ChinaPayments | Fees for paying Australian invoices from Asian digital wallets | Transaction | | Alternative Payments (Payments International) | SaaS fees, top-up voucher facilitation, settlement services, prepaid reloadable card fees; based on transactional value | Transaction + SaaS | | ATX Payments (Malaysia) | Third-party bill and product payment fees | Transaction | | Technology Solutions | Licence fees amortised over contract term; professional services; subscription billing (Emersion, now sold) | Licensing + services | | Interest income | Interest on funds held (A$1.06m FY25; A$1.45m FY24) — presented outside revenue in the EBITDA reconciliation | Float income | Novatti earns almost all of its revenue from transaction-linked payment services, with a smaller recurring program/platform fee component. Per the revenue-recognition note in the FY25 Annual Report: **Product vs. service vs. subscription vs. licensing mix:** Not publicly disclosed in percentage terms. Independent characterisation: following the FY25–FY26 exits, the group is predominantly a transaction-processing services business (estimated majority of revenue), with program/platform subscription fees in Issuing and Acquiring and only residual licensing revenue. There is no physical product revenue of significance. **Gross transaction value (GTV):** Exceeded A$4.2b in FY23 (+46% on FY22; Banking Day reporting of FY23 results). FY25 Annual Report highlights Payments AU/NZ GTV of A$2.6b, up 31% on FY24 excluding Cross Border. A single education customer (UNSW) generated more than A$60m of GTV between November 2025 and July 2026 (FY26 Appendix 4E). ### Value-chain position Novatti sits in the middle of the payments value chain as a scheme-licensed principal (issuer and acquirer) and program manager. It holds direct scheme memberships rather than relying entirely on sponsor banks, which allows it to act as a BIN sponsor/issuer-processor for fintech card programs and as a principal acquirer for merchants. It relies on third parties for processing (a new "tier-one global processor" was integrated into the acquiring platform in H2 FY25), banking/settlement facilities (ANZ is the disclosed banker) and certain white-label platforms (Key Business Risks, FY25 Annual Report). Its distribution is increasingly partner-led (fintechs, platforms, distribution partners). ### Customer types and end-markets | Customer type | Examples disclosed (names withheld by company unless stated) | |---|---| | Fintechs and neobanks | Global fintech using Novatti card issuing in NZ (FY25); Vivi Money (Visa debit card issuance, Q3 FY26) | | Corporates / enterprise | Tier-one Australian telco (multi-year renewal FY25; new contract Q2 FY26); major Asian-based global airline (digital voucher payments, FY25; expanded Q3 FY26) | | Professional services | Leading accounting services firm extending card program from Australia to NZ (FY25) | | Education | University of New South Wales (Alipay acceptance, live November 2025); a major NSW university (international tuition payments); a large university accommodation provider in NZ (ChinaPayments) | | Healthcare / pharmacy | Pharmacy group expanding payment services into NZ operations (Q3 FY26) | | Rewards / loyalty | Digital payment rewards and cashback platform, subsidiary of a major Asian payments fintech (Q3 FY26) | | Merchants (SME to mid-market) | Retail, eCommerce, education and healthcare acquiring customers in implementation (FY26) | **End-markets served:** Australian and New Zealand card issuing (debit/prepaid), merchant acquiring (card-present, eCommerce, alternative payment methods), inbound Asia-to-Australia/NZ wallet payments (international students, tourism), and, via the AUDC stake, regulated stablecoin infrastructure. ### Independent characterisation Novatti is best understood as a sub-scale but licence-rich payments enabler that has been forced by capital scarcity to narrow to the two business lines where its scheme licences confer genuine advantage: Issuing (BIN sponsorship and program management for fintechs and corporates) and Acquiring (with a differentiated Alipay/WeChat Pay acceptance capability, notably in education). Revenue has fallen by roughly 41% between FY25 and FY26 because management deliberately walked away from high-volume, low-margin and higher-risk flows (wholesale cross-border, a low-margin overseas customer). The resulting business is roughly a A$30m revenue, ~51% gross margin operation that is near break-even at underlying EBITDA. A large part of the residual equity value sits outside the operating business in the AUDC stake, which was marked at A$0.80 per share in AUDC's December 2025 Pre-Series A round.

Revenue$0.0B
EmployeesN/A
Market CapN/A
Founded1995
Melbourne, Australia
Norwood

Norwood Systems Limited

Premium
Information Technology

Norwood Systems is a Perth-based micro-cap software company that builds cloud-native, AI-enabled voice service platforms for telecommunications carriers (communication service providers, or CSPs). Its two core platforms are CogVoice™ and OpenSpan™. CogVoice is a carrier-grade voice platform underpinning network voicemail, call completion, agentic IVR and small-business answering services. OpenSpan is a carrier-grade integration layer that connects legacy CSP voice networks to hyperscaler-hosted AI services, supporting applications such as Call Protect (real-time scam/fraud detection), transcription, summarisation and SME assistants. Revenue comes mainly from two Tier-1 Australasian carriers: Optus (Singtel Group) and Spark New Zealand. These are supplemented by paid pilots with a Tier-1 Australian operator (contracted via Microsoft) and a major UK telco, and by legacy consumer app revenue. FY2026 revenue was a record A$2.44m. The company remains loss-making (FY2026 net loss A$0.86m), has negative equity (−A$0.52m), and depends on short-term debt, R&D tax-refund financing and equity raisings. --- ### What the company does Norwood designs, builds and operates software platforms that let telecom carriers deliver new voice services and modernise legacy ones. These services are hosted on public cloud infrastructure (Microsoft Azure and Amazon Web Services) or in customer-controlled cloud environments. The company's current product architecture has two layers: 1. **CogVoice™ — carrier voice platform and applications.** CogVoice was originally developed as Norwood's cognitive-voice platform (marketed in 2022 under the Aïda brand for white-label carrier use). It is now the platform behind Norwood's production carrier deals: - the five-year Optus contract to replace Optus's national legacy voicemail system (announced 18 March 2025, estimated A$2.98m); and - the CogVoice application portfolio: Voicemail, Call Screener/Call Protect, Jobs Agent, SME Assistant, Agentic IVR, and outbound sales agents. 2. **OpenSpan™ — AI services orchestration and integration layer.** OpenSpan was launched in partnership with Microsoft in December 2024. The FY2026 Appendix 4E describes it as a carrier-grade layer between CSP voice networks and cloud-hosted AI services. It supports Call Protect, transcription, summarisation and enterprise voice applications. Third-party summaries of company materials also cite keyword voice activation and live language translation. OpenSpan Call Protect won the APICTA 2025 Gold Award. Alongside these sit legacy assets: **World Voicemail:** a visual voicemail service, white-labelled for Spark NZ since around 2018–2020. **World Apps:** consumer applications — World Phone, World Message, SecondLine, World Secure, World Wi-Fi — sold through Apple and Google app stores. **Corona®:** the original virtual mobile services / roaming platform. ### Company's own description (latest filings, paraphrased) The FY2026 Appendix 4E describes FY2026 as a year of meaningful commercial and operational progress. It cites higher recognised revenue and customer collections, materially lower operating cash outflow, broader and longer carrier relationships, and the move of OpenSpan from technical validation toward repeatable paid-pilot delivery. In the June 2026 quarterly report, the company describes itself as a leading cloud-native AI service platform innovator. Its boilerplate presents Norwood as an innovator in voice communication services that provides conversational and generative AI technologies to carriers. ### Business and revenue model | Revenue model element | Description | FY2026 evidence | |---|---|---| | Platform licence + maintenance (recurring) | Fixed licence and support fees from carriers for hosted voicemail platforms | Spark voicemail revenue A$741.9k; Optus voicemail revenue A$1,071.8k (part recurring, part milestone) | | Usage-based charges (recurring, variable) | Monthly usage fees tied to subscriber volumes | Spark renewal to 30 June 2028 combines fixed licence/maintenance and usage charges (ASX, 15 June 2026) | | Professional services / milestones (project) | Implementation, migration and enhancement work, paid on acceptance milestones | Optus contract paid on performance milestones; A$595k enhancement (June 2026); project revenue A$282.5k | | Paid pilots / proofs of concept | Time-boxed, fee-bearing carrier trials | A$200k Microsoft-contracted Australian pilot; £150k (≈A$285k) UK pilot | | Consumer app subscriptions (legacy) | App-store revenue from World Apps | A$108.4k (declining) | | Platform/other | Corona platform revenue and other | Corona A$230.6k; other A$0.4k | Revenue is recognised across several distinct streams (FY2026 Appendix 4E, Note 1.1). **Analyst characterisation of the mix (FY2026).** - Carrier platform revenue (Optus + Spark): about 74.5% of revenue. - Project/pilot and Corona revenue: about 21.1%. - Consumer apps: about 4.5%. On an economic basis the business is best described as carrier software-as-a-service plus professional services. A clear recurring core exists (the Spark licence/usage and the Optus licence/support components). However, the company does not separately disclose recurring versus non-recurring revenue. ### Value-chain position Norwood is a niche application/platform vendor that sits between: - carrier voice cores (IMS/VoLTE networks supplied by firms such as Ericsson, Nokia and Ribbon); - hyperscaler AI and cloud infrastructure (Microsoft Azure OpenAI/Foundry and Kubernetes Service; AWS); and - carrier retail product teams. It does not own network infrastructure. Its value-add is carrier-grade integration (protocol handling, media gateway functions, resilience and security) plus packaged AI applications that carriers can white-label. Microsoft is both a technology partner and, in the 2026 Australian pilot, a contracting channel: the pilot was contracted through Microsoft rather than directly with the carrier. ### Customer types and end markets | Customer type | Examples (disclosed) | Status | |---|---|---| | Tier-1 mobile network operators (APAC) | Optus (Singtel Group, Australia); Spark New Zealand | Production customers | | Tier-1 operator (Australia, unnamed) | Microsoft-contracted OpenSpan SME pilot | Pilot completed July 2026; production discussions under way | | Major UK telco (unnamed) | OpenSpan + CogVoice paid pilot | Pilot running June to about mid-September 2026; potential Q4 CY2026 launch if approved | | US Tier-1 operator (unnamed) | OpenSpan Call Protect POC | Successful POC; follow-on discussions | | APAC operator (unnamed) | OpenSpan Call Protect paid POC | Successful POC; production terms under discussion | | Consumers and SOHO/SME users | World Apps users; end subscribers of carrier services | Legacy/indirect | End markets: carrier voicemail and call completion; anti-scam call protection; AI-enabled SME telephony (virtual receptionist, jobs agent); agentic IVR and contact-centre routing.

Revenue$0.0B
EmployeesN/A
Market CapN/A
Founded2011
Nedlands, Australia
Northern

Northern Star Resources Limited

Premium
Information Technology

Northern Star Resources is Australia's largest gold producer by market value and output. It sold 1.54Moz in FY26 from three production centres. Kalgoorlie includes the 100%-owned Kalgoorlie Consolidated Gold Mines (KCGM, the "Super Pit") and Kalgoorlie Operations. Yandal comprises Jundee and Thunderbox. Pogo is in Alaska. The company also holds the Hemi development project in the Pilbara, acquired with De Grey Mining in 2025. It holds 88.9Moz of Mineral Resources and 28.4Moz of Ore Reserves (31 Mar 2026), among the largest endowments of any gold miner in a Tier-1 jurisdiction. The investment case rests on the A$1.65 to 1.69bn KCGM mill expansion, which doubles capacity to 27Mtpa and entered commissioning in July 2026, and on Hemi (FID targeted late FY27). The company currently faces a credibility reset. FY26 guidance was cut twice. Founder-era CEO Stuart Tonkin departed. Elliott Investment Management (about 5.6% economic interest) is pressing for board renewal and a strategic review. A new CEO and Chair are taking over. --- ### What the company does Northern Star is a pure-play gold miner. It explores for, develops, mines and processes gold-bearing ore into doré, which is refined into bullion by third-party refiners and sold at spot or under hedge contracts. Silver is a minor by-product. The company owns and operates all its major assets at 100%, a deliberate legacy of its strategy of buying out joint venture partners. It runs open-pit and underground mines feeding owned processing plants. KCGM's Fimiston plant is the largest of these, at a nameplate of about 13Mtpa before expansion and 27Mtpa post-expansion. ### Business and revenue model | Dimension | Characterisation | |---|---| | Revenue type | Almost entirely product sales (gold bullion, minor silver). No service, subscription or licensing revenue. | | Pricing | Price-taker on the global gold price. Realised price reflects spot less forward-sale (hedge) delivery. The hedge book has been run down, and no new hedges were added over the three quarters to June 2025 (June 2025 Quarterly). | | Customers | Bullion banks and refiners (e.g., Perth Mint relationships). Customer concentration is a function of the bullion market structure rather than commercial dependency. | | Value-chain position | Upstream: exploration, mine development, mining, processing. No downstream refining, jewellery or retail exposure. | | Cost structure | Labour, contractors, diesel and power, reagents and consumables, maintenance, government royalties (WA 2.5% plus private royalties; Alaska taxes and tariffs), depreciation and amortisation. Sustaining capital is embedded in AISC. | | Key KPI set | Gold sold (koz), AISC (A$/oz), underlying EBITDA, Cash Earnings (underlying EBITDA less net interest, tax paid and sustaining capital), underlying free cash flow, ROCE, net cash | | End-markets | Gold demand from central banks, investment (ETFs, bars and coins), jewellery and technology. Northern Star's exposure is to the price, not to individual end-use segments. | ### Company self-description In its results materials, Northern Star states its purpose as generating superior returns for shareholders while providing positive benefits for stakeholders, through operational effectiveness, exploration and active portfolio management (FY22 Sustainability Report). It describes itself as a global gold producer with tier-1 assets in Western Australia and Alaska. Its "STARR" values are Safety, Teamwork, Accountability, Respect and Results. ### Independent characterisation Northern Star is a scale consolidator that has evolved into a single-asset-dominated growth story. The Kalgoorlie production centre supplied 844koz of 1,543koz (55%) of FY26 gold sold. KCGM alone holds about 47% of Group Mineral Resources (42.2Moz of 88.9Moz) and 53% of Ore Reserves (15.0Moz of 28.4Moz). Its value is therefore increasingly tied to executing the KCGM expansion and, later, Hemi. The company's historic edge was M&A discipline. It bought distressed or non-core assets from majors (Barrick, Newmont, Sumitomo) at low points in the cycle and lifted their productivity. Its current challenge is different: running very large, complex processing infrastructure and delivering mega-projects. Elliott has argued, and the board has partially conceded through leadership change, that this requires a different operating capability.

Revenue$4.9B
EmployeesN/A
Market CapN/A
Founded2000
Perth, Australia
Northern

Northern Minerals Limited

Premium
Information Technology

Northern Minerals is one of the very few listed, development-stage pure-play heavy rare earth element (HREE) companies outside China. Its 100%-owned Browns Range project in the East Kimberley hosts xenotime-hosted deposits unusually rich in dysprosium (Dy) and terbium (Tb), the two elements that allow neodymium-iron-boron permanent magnets to retain magnetism at high temperatures in EV traction motors, wind turbines and defence systems. A Definitive Feasibility Study (September 2025) outlined an ~11-year operation producing ~17,500 tpa of xenotime concentrate for supply to Iluka Resources' government-backed Eneabba refinery under a binding, conditional offtake for 30,500 t TREO, with Browns Range positioned to supply ~8% of world Dy/Tb. The company holds non-binding support letters from US EXIM and Export Finance Australia, but its path to a Final Investment Decision has been complicated by repeated Federal Treasurer interventions against China-linked shareholders and a deferred AGM. It is a strategically significant but financing-dependent, high-risk, pre-revenue developer. --- ### What the company does Northern Minerals explores for, evaluates and is seeking to develop heavy rare earth deposits, principally at Browns Range in the north-west Tanami region straddling the Western Australia–Northern Territory border, more than 160 km south-east of Halls Creek. Its mineralisation is xenotime (a yttrium-phosphate mineral carrying heavy rare earths) hosted in hydrothermal quartz–hematite veins and breccias within the Archaean Browns Range Metamorphics. The company's current activity set, as described in its financial reports, comprises: advancing Browns Range through Front-End Engineering Design (FEED) toward FID; progressing project funding discussions with domestic and international government agencies and other investors; exploration across its deposits and regional tenure; maintaining exploration and mining tenure; and maintaining the Browns Range pilot plant (in care and maintenance) and camp. ### Company's own description (latest ASX "About" statement, 2026) The company describes itself as owning 100% of the Browns Range Heavy Rare Earths Project, whose deposits are uniquely rich in dysprosium and terbium. It explains that these elements are critical in DyNdFeB magnets for clean energy, military and high-technology applications because they improve magnet resistance to demagnetisation. It calls Wolverine its flagship deposit, which it believes is the highest-grade Dy/Tb ore body in Australia, and states that, following the DFS, it is progressing funding to construct a commercial-scale operation to mine and beneficiate Wolverine ore for delivery to Iluka Resources' under-construction refinery at Eneabba, Western Australia. (Source: ASX announcement boilerplate, 13 August 2026.) ### Business model and revenue model | Dimension | Characterisation | |---|---| | Current revenue model | None from operations. Income is limited to interest on cash/term deposits and minor other income (~A$1.4–1.7M per year, FY2025–FY2026, aggregator data). | | Planned revenue model | 100% product sales: xenotime mineral concentrate (~25% TREO) sold under a long-term supply agreement to Iluka Resources' Eneabba refinery. Pricing expected to reference rare earth oxide prices (basket dominated by Dy/Tb, ~70% of basket value per DFS). | | Product vs service vs subscription vs licensing | Product (mineral concentrate) 100% when in production; no service, subscription or licensing revenue. | | Value chain position | Upstream: mining and beneficiation (concentration). Downstream separation and refining outsourced to Iluka (Eneabba). The company previously operated a pilot hydrometallurgical plant (2018–2021) producing mixed rare earth carbonate, but the DFS flowsheet stops at concentrate. | | Customer types | Single anchor customer (Iluka Resources) under binding conditional offtake; historically, pilot-plant carbonate was sold to international buyers (~1,000 t MREC, 2018–2021). | | End-markets (indirect) | Permanent magnets for EVs and hybrid vehicles, wind turbines, defence/aerospace, industrial motors, consumer electronics; also yttrium for ceramics/phosphors/alloys. | ### Independent characterisation Northern Minerals is best understood as a single-asset, single-offtaker, policy-leveraged development company. Its investment case rests on three pillars: (1) geological scarcity — xenotime-hosted, Dy/Tb-rich hard-rock deposits are rare outside China and Myanmar ionic clays; (2) a downstream route to market via a domestic refinery (Eneabba) that has itself received roughly A$1.6 billion of Australian Government financing support, reducing the classic "concentrate with no buyer" risk; and (3) Western government financing appetite (US EXIM, EFA, potentially NAIF) motivated by China's dominance of heavy rare earth separation and its April 2025 export controls on seven medium/heavy rare earths including Dy and Tb. Against this, the project's base-case economics are modest (pre-tax NPV8 A$187M on A$592M capex, IRR ~12%), meaning the company is heavily geared to price assumptions and to concessional financing; and its share register has been the subject of sustained national-security intervention, which has delayed its AGM and complicated governance.

RevenueN/A
EmployeesN/A
Market CapN/A
Founded2006
West Perth, Australia
North

North Stawell Minerals Limited

Premium
Information Technology

North Stawell Minerals is a micro-cap gold explorer, capitalised at roughly A$7–8 million. It was spun out of the privately owned Stawell Gold Mines in 2020 to explore about 445 km² of granted tenure (504 km² reported at FY2025) along the northern extension of the Stawell Mineralised Corridor in western Victoria. Its thesis is that the basalt-hosted ("Stawell-type") and high-grade structurally hosted ("Mariners-type") gold systems that produced 5.3 Moz at the adjacent Stawell Gold Mine repeat beneath the thin sedimentary cover that masks about 85% of its ground. Geophysics can image the controlling basalts through that cover. NSM holds a modest JORC 2012 Mineral Resource at Wildwood: 87.3 koz at 2.4 g/t Au, 51% Indicated. Its most active exploration front is the Darlington–Caledonia trend, 6–8 km north of the operating Stawell mine, where it has drilled high-grade intercepts such as 2.3 m at 29.18 g/t Au. The company is pre-revenue, funds itself through frequent small equity raisings, and carries an auditor-flagged going-concern material uncertainty. --- ### What the company does NSM's sole business is mineral exploration and evaluation. It explores for gold on tenements in the Stawell Corridor of Victoria, adjacent to the multi-million-ounce Stawell Gold Mine. The FY2025 Directors' Report describes its principal continuing activity as exploration and evaluation at its Stawell Corridor tenements, next to the producing Stawell Gold Mine (FY25 AR, Principal activities). The company's model is the classic junior-explorer model: 1. Raise equity capital. 2. Spend it on geophysics, geochemistry and drilling to define mineralisation and JORC-compliant Mineral Resources. 3. Create value through discovery, resource growth, and an eventual sale, joint venture/farm-out, or (more remotely) self-development. ### Revenue model | Revenue type | FY2024 (A$) | FY2025 (A$) | Comment | |---|---|---|---| | Product sales (gold) | 0 | 0 | No production; no mining or development activity undertaken (Jun 2026 quarterly) | | Services / subscription / licensing | 0 | 0 | Not applicable | | Interest income | 53,531 | 27,737 | Treasury income on cash balances | | Profit on sale of plant and equipment | 0 | 69,821 | One-off disposal (motor vehicles) | | Total other income | 53,531 | 97,558 | FY25 AR, Note 4 | There is no operating revenue. Accounting income consists only of interest and asset-disposal gains. R&D Tax Incentive receipts (A$256,975 in FY2024) are offset against capitalised exploration assets rather than booked as income (FY25 AR, Note 2 and cash flow statement). ### Value-chain position NSM sits at the most upstream point of the gold value chain: grassroots-to-advanced exploration plus resource definition. It has no mine, mill or processing infrastructure. Its strategic proximity to Stawell Gold Mines (SGM) is central to the equity story in three ways: **Shared services:** NSM pays SGM a support-services fee for administrative offices, safety, cleaning and database management. This was A$2,000 per month in H1 FY2026 and A$24,000 in FY2025, down from A$330,000 in FY2024 (FY25 AR Note 21; H1 FY26 Note 7). **Data endowment:** NSM inherited SGM's Magdala geological database. The company values the historic drilling data within its footprint at about A$27M, an estimate based on the replacement cost of drilling (RIU presentation, Aug 2026). **Potential offtake or toll-treatment counterparty:** Management describes the tenements as lying "in the shadow of the headframe", within 5–60 km of an active mining centre (RIU presentation). No offtake, toll-milling or ore-purchase agreement has been disclosed. ### Customer types and end-markets There are no customers. The ultimate end-market for any future product would be the global gold market. Gold traded at about US$4,130–4,180/oz (roughly A$5,950/oz) in early October 2026, according to price-aggregator data. That aggregator is of moderate reliability and the figure is indicative only. ### Company self-description vs. independent characterisation **Company description (paraphrased from Aug 2026 boilerplate):** NSM describes itself as an Australian gold exploration company. It aims to create shareholder value by systematically searching for and evaluating prospective gold exploration and development projects in Australia, while advancing its large-scale gold projects in the Stawell Mineralised Corridor. It notes that its granted tenure totals 445 km², and that it uses the Magdala and Mariners orebodies at Stawell as the exploration model to test the 51 km length of its tenements. **Independent characterisation:** NSM is a capital-constrained, single-district explorer. It has a geologically coherent model, an inherited data advantage, and a high-profile but sub-economic resource at its current scale (87.3 koz). Its quarterly cash burn has fallen to roughly A$0.4–0.9 million. Cash at 30 June 2026 covered only about 1.3 quarters of activity at the then-current spend rate (Kalkine, 31 Jul 2026). The February 2026 strategy update widened the mandate to include other Australian gold exploration and development opportunities. That marks a shift from a pure "Stawell-repeat" story towards a potential project-acquisition vehicle. The register is concentrated: two holders each held about 17–19% at September 2025. The founding sponsor's influence remains strong through Chairman Campbell Olsen, who is also a director of Arete Capital Partners and South Stawell Gold Pty Ltd.

RevenueN/A
EmployeesN/A
Market CapN/A
Founded2019
Stawell, Australia
Noronex

Noronex Limited

Premium
Information Technology

Noronex Limited is a Perth-based junior explorer whose core value lies in one of the largest landholdings in the Kalahari Copper Belt. The company reports about 10,400 km² across central-eastern Namibia and north-western Botswana, targeting sediment-hosted copper-silver deposits at the D'Kar–Ngwako Pan Formation (NPF) contact. Its distinctive feature is a funding model built around South32. A wholly owned South32 subsidiary can earn 60% of the Humpback-Damara Project (Namibia) for A$15M and of the Cgae Cgae Project (Botswana) for A$5M over five years, with Noronex acting as operator and earning management fees. Noronex also holds a 51% interest, with the right to earn up to 80%, in the Etango North uranium licence beside Bannerman's Etango project, and a JORC-reported copper-gold-silver resource at Onaman/Lynx in Ontario. In September 2026 it exercised an option to acquire the Sleitat tin-tungsten-silver project in Alaska. This pivots part of the portfolio toward US critical minerals. Noronex has no revenue from mining, and its cash runway is short. --- ### Company self-description In its standard ASX "About" paragraph, used through 2026, Noronex describes itself as an ASX-listed copper explorer with advanced projects in the Kalahari Copper Belt (Namibia and Botswana) and in Ontario, Canada. It says these projects have collectively seen more than 180,000 m of historical drilling. It highlights its Strategic Alliance Agreement (SAA) with South32 and the two earn-in agreements, under which it manages exploration. It also refers to its exposure to a uranium tenement (EPL 6776, Etango North) in Namibia's hard-rock uranium district (source: ASX announcements dated 20 March 2026, 24 July 2026, 4 and 7 September 2026). From July 2026 the company added the Sleitat tin project in Alaska. ### Independent characterisation Noronex is a project-generator and operator-explorer rather than a producer. Its economic model has five parts: 1. **Acquire large, early-stage land packages** in under-explored belts at low cost, through Namibian EPLs, Botswana prospecting licences and Ontario claims. 2. **Farm out the capital-intensive exploration risk** to a major (South32) in exchange for a minority retained interest (40% post-earn-in) and operator fees (7.5% of programme spend, per Small Caps coverage of the March 2024 deal), plus generative funding of A$200k per year under the SAA. 3. **Monetise non-core advanced assets** to fund corporate overhead. Examples are the Witvlei sale to Joint Era Mining (JEM) and the Dordabis sale to Umino. 4. **Add optionality through opportunistic acquisitions** such as Etango North (uranium) and Sleitat (tin). 5. **Raise equity periodically** to cover the remaining funding gap. ### Revenue model | Revenue type | Nature | Materiality | |---|---|---| | Product sales | None. No mining or processing operations. | Nil | | Operator / management fees | Fees charged to South32 for managing earn-in programmes | Small; recognised as "other revenue" (S&P: A$0.04M FY2024, A$0.37M FY2025) | | SAA generative funding | A$200k per year from South32 for new-target generation in Namibia (SAA expires December 2026) | Included in operating receipts. FY2026 Appendix 5B shows A$546k combined generative funding and operator fees. | | Asset sale proceeds / option fees | Witvlei (JEM) and Dordabis (Umino) | FY2026 investing inflow of A$1,695k from tenement sale proceeds, plus a A$160k net Witvlei option fee | | Earn-in funding | South32 cash advances for programme spend (pass-through, recorded in financing cash flows) | A$4,200k received in FY2026 (Appendix 5B) | ### Value-chain position and customers Noronex sits at the very top of the mining value chain: grassroots-to-advanced exploration. It has no commodity customers. Its "customers" are, in effect, (a) its earn-in partner South32, which pays for exploration and fees, (b) buyers of its non-core projects, and (c) equity investors. The end-markets for its eventual products are copper and silver (electrification and grid infrastructure), uranium (nuclear fuel), and tin and tungsten (electronics solder, defence and critical-minerals supply chains).

RevenueN/A
EmployeesN/A
Market CapN/A
Founded2015
Subiaco, Australia
Nippon

Nippon Kayaku Co., Ltd.

Premium
Information Technology

Nippon Kayaku is a 110-year-old Japanese specialty-chemicals and pharmaceuticals group. Its technology base comes from explosives, dyes, polymers, catalyst design and oncology chemistry. It operates three balanced business domains. Mobility & Imaging (39% of FY2025 sales) makes airbag inflators, seatbelt-pretensioner micro gas generators (MGGs) and squibs, plus optical films and X-ray components. Fine Chemicals (31%) makes semiconductor-grade epoxy and maleimide resins, MEMS resists, inkjet and functional dyes, and acrylic/methacrylic-acid catalysts. Life Science (30%) covers oncology drugs, antibody biosimilars, generics, contract manufacturing and agrochemicals. The company says it holds the top global share in MGGs and acrylic-acid catalysts and a leading share in semiconductor epoxy resins, and it is a leading domestic oncology supplier. In FY2025 it reported record sales of JPY 241.9 bn, with 56% generated overseas. It is now in the first phase of a ten-year plan, Evolution2035, which targets about JPY 500 bn of sales and ROE of 15% or more by FY2035. A cash-rich balance sheet (equity ratio 70%) funds aggressive buybacks. --- ### What the company does Nippon Kayaku manufactures and sells performance chemicals, automotive pyrotechnic safety components, optical and X-ray components, prescription pharmaceuticals (mainly oncology) and agrochemicals. Per the FY2025 Yuho, it reports three segments ("business domains") made up of eight business units: **Mobility & Imaging (M&I):** Safety Systems (airbag inflators, seatbelt-pretensioner MGGs, squibs) and Polatechno (LCD components, LCD-projector components, X-ray analysis equipment components). **Fine Chemicals (FC):** Functional Materials (epoxy and maleimide resins, curing agents, reactive flame-retardant resins, acrylic esters, UV-curable resins, MEMS resists, LCD and semiconductor cleaners, LCD sealants, semiconductor equipment). Colorant Materials (inkjet dyes, inkjet textile dyes, industrial inkjet inks, image-sensor materials, dichroic dyes, near-infrared absorbers, textile and paper dyes, resin colorants, thermal developers, pigment derivatives). Catalysts (acrylic acid, acrolein and methacrylic acid catalysts). **Life Science (LS):** Pharmaceuticals (antineoplastics, biologics, cardiovascular agents, photodynamic diagnostic agents, in-vitro diagnostics, embolic materials, APIs and intermediates, food additives, health-food ingredients, food-quality preservatives, sanitisers). Agro (insecticides, herbicides, fungicides, acaricides, public-health insecticides, soil fungicides, animal repellents). Real Estate (leasing). ### Company's own description (paraphrased from the FY2025 Yuho) The group's corporate vision is "KAYAKU spirit": to keep supplying society with the best products by combining continual progress with conscience. Under the ten-year plan Evolution2035, launched in April 2026, the stated aspiration is to deliver safety, prosperity and inspiration to people and the planet through Kayaku's technologies. The plan aims to create social and economic value together. Management describes combining proprietary "KAYAKU technologies" with business assets accumulated over decades and a culture of taking on challenges. The named technologies are agrochemical synthesis, anticancer and bio, catalyst design, dye synthesis, polymers and explosives. The named business assets are a global supply network, quality assurance, stable supply and technical-service sales. ### Business and revenue model | Dimension | Characterisation | |---|---| | Revenue type | Almost entirely product sales: manufactured goods sold B2B, plus prescription drugs sold through Japanese pharmaceutical wholesalers | | Service revenue | Contract manufacturing (pharma CMO/CDMO, being expanded through the Toyama injectables plant acquired 1 October 2026); minor technical services | | Licensing | Inbound licensing dominates (taletrectinib, necitumumab, darinaparsin, goserelin). Outbound royalty arrangements are mostly intra-group (e.g., inflator/MGG technology licensed to Kayaku (Huzhou) Safety Equipment; colorant technology to Shanghai Kayaku International Trading) | | Subscription | None | | Real estate | Rental income from Port Plaza Nikka (Fukuyama) and Wako Shopping Plaza (Wako, Saitama). Under JPY 2 bn of annual sales (FY2024 guidance basis: JPY 2.0 bn) | | Revenue recognition | On delivery (domestic) or at the agreed delivery point (exports), net of rebates and returns (Yuho FY2025, accounting policies) | ### Value-chain position **Safety Systems:** Tier-2 automotive supplier. Inflators, MGGs and squibs go to Tier-1 airbag and seatbelt module makers (e.g., Toyoda Gosei, a disclosed strategic shareholding and 2018 alliance partner) and through them to global and Chinese OEMs. Vertically integrated back into gas-generant (propellant) production. **Polatechno:** Component maker for projector makers, HUD module makers, X-ray analyser and electron-microscope OEMs. **Functional Materials:** Upstream materials supplier to semiconductor encapsulant makers, substrate and laminate makers, MEMS and image-sensor fabs. Also supplies semiconductor back-end equipment (via Teikoku Taping System). **Colorants:** Dye supplier to printer OEMs, ink makers, textile printers and thermal-paper makers. **Catalysts:** Supplies proprietary oxidation catalysts to acrylic-acid and methacrylic-acid producers. **Pharmaceuticals:** Integrated Japanese marketer and manufacturer of oncology drugs (in-licensed innovative drugs, biosimilars, generics), with API/intermediates export and contract manufacturing. **Agro:** Discovery, formulation and sale of crop-protection actives (e.g., flometoquin), domestically and overseas. ### Customer types and end-markets | End-market | Segment | Customer type | |---|---|---| | Automotive passive safety | M&I | Tier-1 airbag/seatbelt module makers; Chinese domestic OEM programmes are a key growth driver (Yuho FY2025) | | Automotive displays (HUD) | M&I | HUD module makers | | Projectors, analytical instruments | M&I | Projector OEMs; X-ray analyser and electron-microscope OEMs | | Semiconductors / AI servers / 5G-6G substrates | FC | Encapsulant, laminate and substrate makers; MEMS and image-sensor fabs | | Printing (consumer, industrial, textile), thermal paper | FC | Printer OEMs, ink formulators, textile printers, thermal-paper makers | | Acrylic monomers | FC | Acrylic-acid and methacrylic-acid producers | | Oncology care (Japan) | LS | Hospitals via wholesalers (Suzuken, Toho, Medipal, Alfresa and Vital KSK are disclosed strategic holdings) | | Agriculture | LS | Distributors and growers (Japan and overseas) | ### Independent characterisation Nippon Kayaku is best understood as a portfolio of niche, mid-cap leadership positions linked by shared chemistry rather than by end-market. Its earnings are cyclically diversified. Automotive volumes, semiconductor inventory cycles and Japanese drug-price revisions rarely trough together. The exception was FY2023, when a semiconductor downturn, steep biosimilar price cuts and a large in-licensing payment coincided and operating margin fell to 3.6%. The structural issues are threefold. First, M&I margins are exposed to pass-through lags on raw materials (gold and explosive components are cited). Second, the pharmaceutical franchise relies on generics and biosimilars, which suffer price revisions under Japan's NHI system. Third, capital efficiency has been weak: ROE stayed below 8% for most of FY2021 to FY2024. Evolution2035 Phase 1 is an explicit attempt to rebuild the portfolio toward higher-value products (new oncology drugs, CDMO, advanced semiconductor resins) and inorganic growth.

Revenue$1.6B
Employees5,946
Market CapN/A
Founded1916
United States, North America
Nine

Nine Entertainment Co. Holdings Limited

Premium
Information Technology

Nine is Australia's largest locally owned, cross-platform media group. After an aggressive FY26 portfolio reset, it is organised around three engines. The first is Streaming & Broadcast: the Nine Network free-to-air channels, the 9Now BVOD platform, and Stan, the country's leading local subscription streaming service with about 2.3m paying subscribers. The second is Publishing: The Sydney Morning Herald, The Age, The Australian Financial Review, Brisbane Times, WAtoday, nine.com.au and Drive, with about 510k subscribers. The third is Outdoor: QMS, acquired on 31 March 2026 for A$850m, a digital-led billboard and street-furniture operator in Australia and New Zealand. Having exited Domain, talk radio, regional TV ownership and Pedestrian, Nine now presents itself as a "digital-first" premium content and audience-data company spanning "Sofa to Street". Management expects growth assets (Stan, 9Now, Digital Publishing, Outdoor) to supply more than 60% of revenue and about 70% of EBITDA in FY27. The company is anchored by marquee sport (NRL to 2034, the Premier League on Stan, cricket, tennis, the Olympics) and remains highly exposed to a structurally declining linear-TV advertising market. --- ### What Nine does Nine creates, acquires and distributes premium news, sport and entertainment content, and monetises audiences through advertising and subscriptions. Licensing is an emerging third leg. After FY26 the group has four reporting lines. 1. **Total Television (Broadcast TV + 9Now).** - Owns and operates the Nine Network metro free-to-air licences in Sydney, Melbourne, Brisbane, Adelaide and Perth (ACMA register). - Multichannels: 9, 9Go!, 9Gem, 9Life and 9Rush. - 9Now is the free ad-supported streaming (BVOD) platform. - Regional coverage now runs entirely through affiliates. WIN Network owns and operates NBN (Northern NSW/Gold Coast) and Darwin since 2 June 2026. Nine retains 50% of gross NBN advertising revenue and 10% of Darwin advertising revenue, and acts as WIN's agent for national sales in those markets (AdNews, 15 Apr 2026). 2. **Stan.** Subscription video on demand. - Stan Entertainment: general entertainment, Stan Originals and licensed library. An ad-supported, lower-priced tier launched 1 August 2026. - Stan Sport: an add-on carrying the Premier League from August 2025, UEFA Champions League, tennis Grand Slams, the Winter Olympics (Milano Cortina 2026) and Super Rugby. It has carried advertising since H1 FY26. 3. **Publishing.** - Metro mastheads: SMH, The Age, AFR, Brisbane Times, WAtoday. - The nine.com.au portal, relaunched 1 June 2026. - Drive, an automotive content and marketplace business. - Content licensing to AI and enterprise: Microsoft Copilot (July 2026) and domestic corporates using Nine content to ground in-house LLMs. 4. **Outdoor (Nine Outdoor / QMS).** Large-format digital billboards and street furniture in Australia and New Zealand. Contracts include City of Sydney street panels and Auckland Transport street furniture. ### Company's own description (FY26 materials, paraphrased) Nine describes itself as a "unique, cross-platform digital media proposition" (Macquarie Conference, May 2026). Its premium content, unique audience data and integrated experiences are meant to deepen connection with consumers and advertisers. The FY26 strategic moves are framed as making Nine "higher growth and more resilient", shifting weight towards growth and digital assets and away from "structurally challenged and smaller assets" (FY26 Results Announcement, CEO commentary). At the January 2026 portfolio announcement, management articulated the goal of being "Australia's leading, digital first media business" (AdNews, 17 Apr 2026). ### Revenue model | Revenue type | Main sources | Approx. weight (FY26 continuing, A$2,189.0m) | Notes | |---|---|---|---| | Advertising – broadcast TV | Nine Network metro FTA, regional affiliate share | Broadcast TV revenue A$817.1m (~37%) | Structurally declining. Underlying ex-Olympics Total TV revenue down about 2% in FY26. | | Advertising – digital video | 9Now, Stan Sport ads, HBO Max ad sales agency | 9Now A$209.7m (~10%) plus a Stan ad component (undisclosed) | Total streaming ad revenue sold grew about 20% in H2 FY26. | | Subscription – video | Stan | Stan A$569.0m (~26%), predominantly subscription | ARPU +8% in FY26 | | Subscription – news | Mastheads digital and print subscriptions | Part of Publishing A$517.5m (~24%) | Digital subscription revenue +15% in FY26 | | Advertising – publishing | Print and digital display, programmatic, nine.com.au, Drive | Part of Publishing | Print ads −12%, digital ads −8% in FY26 | | Outdoor advertising | QMS billboards and street furniture | A$77.4m (3 months; ~4%). Pro forma full-year A$295.4m. | Leases are a material cash cost: A$29m in the 3 months owned | | Licensing | AI/LLM content licences, content sales, News Media Bargaining-type deals | Not separately disclosed | FY27 guidance assumes licensing revenue at a level comparable to FY26 | Subscription revenue grew 12% group-wide in FY26 (FY26 Results Announcement). On a pro forma FY27 basis, management expects growth assets to supply more than 60% of revenue and about 70% of EBITDA. ### Value-chain position and customers Nine is vertically integrated from content creation to distribution. It produces news and current affairs in-house, commissions and produces local entertainment formats (Married at First Sight, The Block, Lego Masters, Love Island Australia), and acquires sports and international rights. It then sells audiences across owned platforms through a single sales organisation, and is building a "total trading platform" and Nine Ad Manager self-serve tooling. **Advertiser customers:** media agencies and national brands; SMEs through self-serve; retail media partners (for example a Metcash retail media partnership launched with the Nine–QMS combination). **Consumer customers:** Stan and masthead subscribers, plus free-to-air and BVOD viewers. **Enterprise customers:** Microsoft; corporates licensing content for internal AI. **B2B partners:** WIN (affiliate fees and program supply); HBO Max (Nine sells HBO Max advertising under a renewed sales agreement). **End markets:** Australian TV advertising (FTA plus BVOD); SVOD; news publishing (subscriptions plus advertising); out-of-home advertising in Australia and NZ; emerging AI content licensing. ### Independent characterisation Nine is best understood as a cash-generative but shrinking linear-TV franchise, used to fund and feed three digital growth engines (Stan, digital mastheads, QMS). Sport rights are the glue: a stated A$1bn a year spend on sports rights and production (CEO, July 2026). The investment case depends on whether the growth engines can outrun broadcast decay. FY26 showed the pattern clearly: Total TV EBITDA fell 12% while Stan rose 34% and QMS 18% pro forma. The decisive variables are the slope of FTA advertising decline, Stan's ability to hold subscribers and ARPU after the ad-tier launch, and QMS synergy delivery. AI licensing and the News Bargaining Incentive are optionality, not yet earnings drivers.

Revenue$1.4B
EmployeesN/A
Market CapN/A
Founded1956
North Sydney, Australia
Nickel

Nickel Industries Limited

Premium
Information Technology

Nickel Industries is an ASX-listed, Indonesia-based nickel producer that has grown, in eight years since its 2018 IPO, from a single-line nickel pig iron (NPI) operator into one of the larger listed nickel platforms outside China and Russia. It produced 133,469 tonnes of nickel metal in FY2025. Its asset base combines a captive laterite ore source (80% of the Hengjaya Mine, with a 2026 sales quota of 14.3 million wet tonnes), four 80%-owned rotary kiln electric furnace (RKEF) complexes making NPI and nickel matte, and a growing portfolio of high-pressure acid leach (HPAL) interests producing Class 1 battery- and aerospace-grade nickel. These are HNC (10%), the newly commissioned 72,000 tpa ENC (46%), and pending stakes in TMI (17.5%) and CNE (36%). It is effectively the only Western-listed pure-play exposure to Indonesia's Tsingshan-anchored industrial-park model. Its largest shareholders are Tsingshan affiliate Shanghai Decent and Jardine/Astra group's United Tractors, which gives it strategic backing, low capital intensity and an unusually high exposure to Indonesian policy. --- ### Company's own description The company's standard boilerplate (ASX announcements, 2025–2026) describes Nickel Industries as an ASX-listed company owning "a portfolio of mining and low-cost downstream nickel processing assets in Indonesia". It has four RKEF projects producing nickel matte for the electric vehicle (EV) supply chain and NPI for the stainless-steel industry. It has a 10% interest in the Huayue Nickel Cobalt (HNC) HPAL project producing mixed hydroxide precipitate (MHP). Its next transformative step is Excelsior Nickel Cobalt (ENC), a next-generation HPAL project able to produce MHP, nickel and cobalt sulphate, and nickel cathode, with expected output above 72,000 tonnes of nickel metal a year. The FY2025 Annual Report describes the group as having "become a globally significant, low-cost producer" of NPI that has diversified into nickel matte and MHP. Its assets are the Hengjaya Nickel, Oracle Nickel and Ranger Nickel RKEF projects in IMIP, the Angel Nickel RKEF project in IWIP, the Hengjaya Mine, and its HPAL interests. ### Independent characterisation Nickel Industries is best understood as a minority-partner, capital-light co-investor in Tsingshan's Indonesian industrial ecosystem, now evolving into an integrated miner-processor. Four structural features define the model: 1. **Partner-built, partner-guaranteed processing.** Every RKEF and HPAL asset was designed, built and in most cases operated by Tsingshan-group entities (Shanghai Decent and affiliates). Nickel Industries acquired equity stakes at pre-agreed prices, often with construction-cost guarantees. Examples include the US$965 million capped construction guarantee on TMI and the ENC capex guarantee from Shanghai Decent. This has let NIC scale nickel output roughly 15-fold since IPO without carrying EPC risk. 2. **Industrial-park co-location.** Assets sit inside IMIP and IWIP, sharing captive coal and power, ports, sulphur and limestone supply and offtake logistics. Unit costs are therefore structurally at the bottom of the global cost curve, but NIC's operational destiny is tied to park-level infrastructure and policy. 3. **Upstream integration via Hengjaya and Sampala.** The 80%-owned Hengjaya Mine sells saprolite to NIC's RKEFs and limonite to HPAL plants. 2026 Indonesian policy changes (higher ore benchmark prices, the HPM; quota rationing, the RKAB) shifted margin from smelters to miners. That made the mine NIC's fastest-growing earnings contributor in 2026: record Q2 2026 mine EBITDA of US$45.7 million. The Sampala project (resource of 1,095 million wet tonnes at 1.24% Ni) is the long-term ore engine and will be the exclusive feed to CNE. 4. **Product transition from Class 2 to Class 1.** In FY2025 most nickel was NPI for stainless steel. The ENC start-up (first MHP July 2026, first cathode August 2026) and the TMI and CNE stakes shift the mix toward battery and aerospace-grade products. ENC's cathode carries a 10-year supply arrangement linked to Sphere Corp., a supplier to SpaceX. ### Business and revenue model | Revenue stream | Nature | Model | Primary customers | |---|---|---|---| | NPI sales (RKEF) | Commodity product, Class 2 nickel (~11–12% Ni grade) | Product sales priced off LME nickel / Chinese NPI indices | Stainless-steel mills within IMIP/IWIP (Tsingshan-affiliated); e.g. 81% of ONI Q1 2026 volume delivered to PT Glory (Q1 2026 Quarterly) | | Nickel matte (RKEF, converted lines) | Intermediate for refining into battery chemicals | Product sales at payable % of LME | Chinese/Indonesian refiners in the battery chain | | Nickel ore sales (Hengjaya Mine) | Saprolite and limonite ore | Volume x HPM-linked price; constrained by annual RKAB quota | NIC's RKEFs, third-party smelters and HPAL plants in IMIP | | MHP (HNC; ENC from July 2026) | Class 1 intermediate | Payable % of LME (MHP payables ~80–90%) | Battery precursor makers | | Nickel cathode and sulphate (ENC, from August 2026) | Class 1 refined products | LME/SHFE-linked; LME/SHFE brand registration pending | Aerospace (Sphere/SpaceX offtake), battery and alloy markets | | MHP trading division | Merchant trading of MHP | Margin on trading | Not publicly disclosed | | Equity-accounted income / dividends | Minority HPAL stakes (HNC 10%) | Dividends; maiden HPAL dividend of US$3.5m received in Q2 2026 | n/a | The model is 100% product sales: no services, subscription or licensing revenue. Earnings are driven by (i) the LME nickel price, (ii) the spread between product prices and ore/power/reductant costs, (iii) RKAB quota volumes and HPM ore prices, and (iv) HPAL payables and sulphur costs. ### Value-chain position and end-markets NIC spans mine (ore) to refined Class 1 metal, but not downstream manufacturing. End-markets: **Stainless steel:** (largest end-use of primary nickel globally). NIC's NPI goes here. **EV batteries:** (nickel-rich NCM/NCA cathodes) through MHP, sulphate and matte. **Aerospace and superalloys:** through ENC cathode (Sphere Corp. partnership, January 2026). **Nickel ore:** as a merchant market inside Indonesia.

RevenueN/A
EmployeesN/A
Market Cap$2.5B
Founded2007
Sydney, Australia
Nib

Nib Holdings Limited

Premium
Information Technology

nib is Australia's fourth/fifth-largest private health insurer by market share and a leading trans-Tasman health funder, covering 1.95 million people across Australia and New Zealand at 30 June 2026. Its core is the Australian Residents Health Insurance (arhi) business — a digitally led, multi-channel insurer that has consistently grown above system through brokers, comparison sites, white-label partners and its own brand. Around this core nib has built "adjacent" businesses: International health insurance for students and temporary workers (including the Pacific Australia Labour Mobility scheme), nib New Zealand, NDIS plan management (nib Thrive) and nib Health Services (Honeysuckle Health, Midnight Health, ItsMyGroup). In FY26 it completed its exit from travel insurance, sharpening its identity as a pure-play health insurance and health services group. Its strategic thesis — moving from "payer to partner" — is to use data, AI, provider networks and health management programs to lower costs and improve outcomes, defending margins in a regulated, inflationary industry. --- ### Company's own description In its interim report, nib describes the Group's principal activities as being a private health insurer in Australia and New Zealand, underwriting and distributing private health insurance to residents and to international students, workers and visitors, alongside complementary health and disability-related services (2026 Interim Report, Directors' Report). The FY26 results announcement frames the mission as helping customers "access and navigate healthcare with confidence", with a stated forward focus on customer value, affordability, access to care, sustainable growth, provider partnerships, care navigation, and the use of technology, data and AI (FY26 ASX Announcement, CEO statement). ### Independent characterisation nib is fundamentally a short-tail, community-rated health insurance underwriter whose earnings are driven by (i) policyholder growth, (ii) the annual government-approved premium increase (5.47% effective 1 April 2026), (iii) claims inflation and utilisation, (iv) risk equalisation transfers in the Australian community-rated system, (v) operating expense efficiency, and (vi) investment returns on regulatory capital and float. Around 78% of FY26 insurance revenue came from the Australian residents business ($3,012.7m of $3,685.7m Group insurance revenue — FY26 ASX Announcement). ### Revenue model mix (FY26) | Revenue type | FY26 (A$m) | Share of total income (%) | Nature | |---|---|---|---| | Insurance revenue (all insurance segments) | 3685.7 | 95.6 | Premium-based, annual/monthly policies (subscription-like recurring revenue) | | Other income | 169.1 | 4.4 | Fees (NDIS plan management fees at nib Thrive $55.0m), health services operating income ($25.4m), distribution commissions, other | | Total income | 3854.8 | 100.0 | — | Source: FY26 ASX Announcement, Group financial performance table. Net investment income ($57.0m) is reported below operating profit and is excluded from "total income" above. ### Value-chain position nib sits at the funder/payer layer of the health value chain: it collects premiums, pays benefits to hospitals, medical specialists and extras providers (dental, optical, physio, audiology, mental health), and increasingly contracts with providers (multi-year hospital agreements covering >80% of hospital spend per 1H26 webcast; "First Choice" preferred-provider network; Known Gap/No Gap specialist arrangements). Through Health Services it moves into care navigation and delivery (telehealth, virtual health management programs via Honeysuckle Health, Midnight Health) and distribution technology (ItsMyGroup platform supporting 18 PHI brands and facilitating >10% of industry PHI sales — FY26 ASX Announcement). ### Customer types and end-markets | Customer type | Segment | End-market | |---|---|---| | Australian resident individuals, couples, families | arhi | Australian private health insurance (hospital + extras) | | International students (OSHC), temporary graduates, skilled workers, PALM scheme workers | International health insurance | Australian overseas visitor/student health cover; NZ international cover | | New Zealand residents (individual and corporate/group schemes) | nib New Zealand | NZ private medical, life and living insurance | | NDIS participants (plan management) | nib Thrive | Australian disability services (NDIS plan management) | | Insurers, employers, governments (B2B), and nib members | nib Health Services | Health management programs, telehealth, PHI distribution technology | | White-label partners, brokers, comparison sites | Distribution across segments | Intermediated insurance distribution | | Travellers (until Sept 2026) | nib Travel (divested) | Travel insurance — now distribution-only via Allianz Partners partnership |

RevenueN/A
EmployeesN/A
Market CapN/A
Founded1952
Newcastle, Australia
NGECapital

NGE Capital Limited

Premium
Information Technology

NGE Capital is a micro-cap, internally managed listed investment company that runs a concentrated, benchmark-agnostic portfolio of roughly 12–18 listed equities across Australia and offshore markets. It describes its approach as event-driven and value-oriented, built on fundamental analysis and a willingness to hold cash when nothing compelling is available. The vehicle is controlled in substance by its investment team: Executive Chairman and CIO David Lamm and Portfolio Manager Adam Saunders, both also of Kentgrove Capital. Directors held 16.8% at end-2025, and Lamm family interests appear repeatedly on the register. NGE's distinguishing features are an uncommon degree of portfolio transparency in monthly NTA statements, a cost structure tied to a 10% share of NTA growth above a high-water mark, and residual Australian tax losses from its earlier life as PNG oil explorer New Guinea Energy. Since becoming a LIC in November 2016, NTA per share has compounded about 12.6–13.6% a year net of costs, ahead of the ASX 200 Accumulation Index. The shares nonetheless persistently trade around 20% below pre-tax NTA. --- **What the company does.** NGE invests its own balance sheet, roughly A$55–60m, in listed securities. It has a flexible mandate that it describes as broad as the ASX Listing Rules allow. It can invest across geographies, asset classes, industries and market capitalisations, and it may in principle use unlisted securities, leverage and short-selling (all listed as risk categories in the FY2025 Annual Report). In practice, every portfolio position at 31 December 2025 and 30 June 2026 was a Level 1 listed equity, there was no leverage, and no short positions were disclosed. **Company's own description (FY2025 Annual Report).** NGE presents itself as a vehicle that gives investors access to a concentrated, high-conviction, actively managed portfolio, focused mainly on ASX and international equities, with the aim of strong risk-adjusted returns over the medium to long term. Its four stated principles are: 1. invest only in compelling opportunities, otherwise hold cash; 2. invest based on fundamental analysis; 3. target strong returns with an adequate margin of safety; 4. hold a concentrated portfolio of high-conviction positions. The company explicitly targets event-driven special situations: M&A, asset sales, strategic reviews, demergers, leadership or strategy changes, and capital management events such as buybacks, capital returns and special dividends. **Business and revenue model.** NGE has no operating revenue. Its "revenue from ordinary activities" under ASX reporting is the sum of: The product, service, subscription and licensing mix is therefore not applicable. Economically, 100% of value creation comes from investment returns. **Cost model.** NGE does not pay an external manager. Costs are employee remuneration (fixed salaries of about A$0.55–0.60m a year, including superannuation), a short-term incentive (STI) pool equal to 10% of growth in pre-tax NTA above a high-water mark (adjusted for buybacks and capital raisings), and other overheads of about A$0.35m a year excluding FX (directors' fees, audit, listing, insurance, data and brokerage). The STI is functionally equivalent to a performance fee paid to the internal team. **Value-chain position.** NGE sits at the end-investor level of the capital-markets value chain. It is a permanent-capital, closed-end vehicle that buys secondary-market listed equities and occasionally participates in placements and rights issues (for example Alliance Aviation and Eureka Group in August–September 2026). **Customer types and end-markets.** The "customers" are NGE's shareholders: 893 holders at 31 January 2026, down from 1,040 in February 2023, with the top 20 holding 60.9%. The register is dominated by family offices, private companies, self-managed super funds and nominee accounts, plus a small institutional holding from Perpetual Corporate Trust as custodian for the Affluence LIC Fund (1.0m shares, 2.92%). The end-markets "served" are the sectors NGE invests in. At 31 August 2026 these were uranium, gold and gold mining services, offshore drilling and energy, consumer and specialty finance, industrial and diversified real estate, aviation services, and early childhood education. **Independent characterisation.** NGE is best understood as a closely held, founder-run micro-cap investment vehicle with three defining traits: **A deep-value, contrarian, real-asset tilt:** About half the portfolio has been in commodity-linked exposures in recent years: uranium, gold, tin, manganese, potash and oil and gas. - **Event-driven situations in neglected small caps**, such as Pioneer Credit, Embark Early Education, Alliance Aviation, Indiana Resources and Danakali. **Very high transparency:** for its size, with named holdings, weights and thesis commentary published monthly. The structure carries two chronic frictions: a persistent discount to NTA, and a fixed-cost base that is large relative to a ~A$55m portfolio. The company mitigates both partly through an open-ended buyback and the tax shelter provided by legacy losses.

RevenueN/A
EmployeesN/A
Market CapN/A
Founded2005
Melbourne, Australia
NewPeak

NewPeak Metals Ltd.

Premium
Information Technology

NewPeak Metals is a Brisbane-based junior explorer that, over 2024–2026, has shed a scattered portfolio across six countries and reorganised around one flagship asset: the 100%-owned Las Opeñas gold-polymetallic project in San Juan Province, Argentina. Las Opeñas sits in the El Indio Belt, about 70 km south-east of the Veladero mine owned by Barrick and Shandong. In 2026 the project returned two consecutive drill intercepts of more than 650 m from surface: 663 m at 0.42 g/t AuEq in hole LODH-023 and 657 m at 0.30 g/t AuEq in hole LODH-027. On that basis management describes it as a large-scale, bulk-tonnage gold-zinc-silver system. The company has a secondary gold project at Tansey in south-east Queensland and a 35% interest in the Cachi gold project in Santa Cruz, Argentina. It also holds uranium/REE optionality at Treuer Range (Northern Territory) and George River (Canada). Historically NewPeak funded itself by selling down its stake in Lakes Blue Energy NL. It is now funded mainly through equity placements. The investment case is a binary, discovery-driven exploration story. --- ### Company's own description The FY2025 annual report describes the group as a mineral resource company that explores for, acquires and develops resource projects. According to Morningstar's summary of filed disclosures, it operates in one business (mining industry) and three geographic locations (Australia, Canada and the Americas). The portfolio named in current disclosures is: - Las Opeñas Gold - Cachi Gold - Tansey Gold - Treuer Range Uranium-Vanadium - George River Uranium-REE-Scandium The FY2025 annual report frames that year as one of "significant transformation" under a "Rejuvenation Strategy" that repositioned the company for future growth. ### Independent characterisation NewPeak is a pure-play greenfield and brownfield mineral explorer with no production, no operating revenue and no near-term path to cash flow from operations. Its business model is the standard junior-explorer model: 1. Acquire prospective tenure cheaply, using scrip or small cash amounts. 2. Spend risk capital on mapping, geochemistry, geophysics and drilling. 3. Convert positive results into a JORC (2012) Mineral Resource. 4. Monetise through a sale, joint venture, earn-in, or (rarely) development. **Revenue model.** There is no product, service, subscription or licensing revenue. Reported "other revenue" has been immaterial (about A$20–25k in FY2023–FY2024 on aggregator data). The company's economics come from: **Equity issuance:** placements, rights issues and debt-for-equity conversions. - **Monetisation of its investment in Lakes Blue Energy NL (ASX: LKO).** This produced a large accounting gain in 1H FY2026 after LKO resumed trading. **Potential future asset sales or farm-outs:** The company is reviewing strategic options for Treuer Range and George River. **Value-chain position.** The company sits at the very front of the mining value chain: exploration and discovery. It is upstream of resource definition, feasibility, development, mining, processing and metal sales. **Customers and end-markets.** NewPeak has no customers in the conventional sense. Its eventual "buyers" are mid-tier and major gold and base-metal producers (as acquirers or JV partners) and equity investors. The ultimate end-markets for its target commodities are: - Gold: investment and jewellery - Zinc: galvanising - Silver: industrial and photovoltaics - Uranium: nuclear fuel - Rare earths and scandium: magnets, alloys and solid-oxide fuel cells Management explicitly positions the zinc and silver content at Las Opeñas against the US Geological Survey's 2025 critical-minerals designation (MD Mark Purcell, 6 July 2026).

RevenueN/A
EmployeesN/A
Market CapN/A
Founded1995
Brisbane, Australia
Neurotech

Neurotech International Limited

Premium
Information Technology

Neurotech International is a micro-capitalisation, single-asset, clinical-stage biopharmaceutical company focused on paediatric neurological and neurodevelopmental disorders. Its sole development asset, NTI164, is a proprietary, GMP-grade, multi-constituent oral cannabinoid formulation rich in cannabidiolic acid (CBDA) with select minor cannabinoids and very low THC (0.08% per the Rett publication title), positioned on a neuroinflammation and immune-dysregulation mechanism rather than as a conventional CBD product. After completing a 54-patient Phase II/III study (HARMONY) in Autism Spectrum Disorder (ASD) and open-label Phase I/II studies in Rett syndrome and PANDAS/PANS, the company dosed its first patient in the pivotal Phase 3 "Beyond Harmony" ASD trial in September 2026 across six Australian sites. It holds US FDA IND clearance, US Orphan Drug and Rare Pediatric Disease Designations in Rett syndrome, and an EU orphan designation. Neurotech generates no product revenue, relies on R&D tax incentives and equity, and its value is almost wholly contingent on Phase 3 success and partnering. --- **Company's own description (FY2026 Annual Report, Principal Activities, paraphrased).** Neurotech describes itself as a clinical-stage biopharmaceutical development company concentrated mainly on paediatric neurological disorders, built around a broad-spectrum oral cannabinoid drug therapy, NTI164. It highlights completion of a randomised, double-blind, placebo-controlled Phase II/III trial in ASD with statistically significant and clinically meaningful benefits across several validated measures and a favourable safety profile, completion of Phase I/II studies in ASD, PANDAS/PANS and Rett syndrome, and ethics clearance for a Phase III ASD study. The notes to the accounts additionally describe the group as a biotechnology company conducting clinical studies into the neuroprotective, anti-inflammatory and neuromodulatory activity of its proprietary cannabis strains. **Independent characterisation.** Neurotech is best understood as a "virtual" drug developer: it owns intellectual property, regulatory dossiers and clinical data, while outsourcing cultivation/extraction and GMP manufacture (the FY2026 AR cites production across three Australian facilities), clinical operations (hospital sites, CROs), toxicology (GLP studies) and analytics. Its cost base is overwhelmingly clinical: of A$9.05m of FY2026 R&D expense, A$8.43m (93%) was the clinical programme. The company has no sales force, no manufacturing plant and no meaningful revenue. **Business model and revenue model.** **Value-chain position.** Upstream: proprietary plant genetics (historically described as "NTI/Dolce" strains) and extraction to a standardised CBDA-rich extract, produced by third-party Australian GMP facilities. Midstream: clinical development, regulatory affairs and IP. Downstream (future): either a licensed commercial partner or a self-commercialised specialty paediatric neurology product in Australia, with partner-led commercialisation more likely in the US/EU. **Customer types and end-markets.** Prospective customers are paediatric neurologists, developmental paediatricians and psychiatrists treating children with moderate-to-severe (Level 2 and 3) ASD; rare-disease specialists (Rett syndrome); and paediatric immunology/neuropsychiatry clinicians (PANS/PANDAS). Current "customers" are limited to AP-program patients in Australia.

RevenueN/A
EmployeesN/A
Market CapN/A
Founded2016
Melbourne, Australia
Neuren

Neuren Pharmaceuticals Limited

Premium
Information Technology

Neuren Pharmaceuticals is a New Zealand-incorporated, Melbourne-headquartered biopharmaceutical company that discovers and develops orally administered synthetic analogues of naturally occurring peptides derived from insulin-like growth factor 1 (IGF-1), targeting serious neurodevelopmental disorders of early childhood. Its first drug, trofinetide, is the only approved therapy for Rett syndrome in the US, EU, Canada and Israel. Acadia Pharmaceuticals markets it under an exclusive worldwide licence as DAYBUE®, DAYBUE® STIX and, in the EU, DAYBU®. In return Neuren receives tiered royalties and milestones, which converted the company from a cash-consuming developer into a profitable, debt-free royalty business with A$287m of cash. That cash flow now funds the company's second asset, NNZ-2591 (ercanetide), which is in the first-ever Phase 3 trial in Phelan-McDermid syndrome and in development for Pitt Hopkins syndrome, Angelman syndrome and hypoxic-ischemic encephalopathy. In 2026 Neuren introduced a semi-annual, fully franked dividend, which makes it a rare dividend-paying ASX biotech. --- ### Company's own description In its 2026 ASX announcements, Neuren describes itself as "developing new drug therapies to treat multiple serious neurological disorders caused by genetic abnormalities or brain injury, that have no or limited approved treatment options," with therapies that "target the critical role of Insulin-like growth factor 1 (IGF-1) in the brain, using orally administered analogs of naturally occurring peptides" (About Neuren boilerplate, H1 2026 announcement, 26 Aug 2026). ### Independent characterisation Neuren is best understood as a hybrid royalty vehicle and clinical-stage developer. It has two economic engines. 1. **Trofinetide royalty and milestone stream (out-licensed, commercial).** Neuren does not manufacture, sell or distribute trofinetide. Acadia holds an exclusive worldwide licence: North America since 2018, extended to the rest of the world in 2023. Acadia funds all development, regulatory, manufacturing and commercial activity. Neuren's economics consist of: - **North America:** tiered, escalating double-digit royalties on net sales. The first tier is 10%, which was the effective rate in 2023 according to the Q4 2023 Activity Report. Sales milestones are payable when calendar-year North American net sales cross escalating thresholds. The first, US$50m at the US$250m threshold, was earned in FY2024. The next is US$50m when North American net sales exceed US$500m in a calendar year (H1 2026 announcement). - **Europe:** US$35m on first commercial sale, up to US$170m of sales milestones, and tiered royalties from mid-teens to low-20s percent of European net sales (H1 2026 announcement). - **Japan:** US$15m on first commercial sale for Rett, US$4m on first commercial sale for a second indication, up to US$110m of sales milestones, and mid-teens to low-20s percent royalties (H1 2026 announcement; 24 Apr 2024 announcement). - **Other ex-North America territories:** royalties and milestones under the 2023 global licence expansion, on terms summarised in Neuren's licence disclosures. - **Fragile X:** a further US$55m milestone if Acadia develops trofinetide for Fragile X syndrome (Q4 2023 Activity Report). 2. **NNZ-2591 (ercanetide) development (wholly owned, clinical).** Neuren keeps worldwide rights to NNZ-2591 in all indications except Rett syndrome and Fragile X syndrome, which are licensed to Acadia. Neuren funds and runs NNZ-2591 development itself. It is the main source of the company's long-term optionality, including potential Rare Pediatric Disease Priority Review Vouchers (PRVs), which Neuren would own 100% of. ### Revenue model mix | Revenue type | Nature | FY2025 status | |---|---|---| | Royalties | Recurring, quarterly, US$-denominated, tied to DAYBUE net sales | A$64.6m. This is about 76% of total revenue from ordinary activities (derived from the FY2025 Appendix 4E). | | Milestones (development, first sale, sales thresholds) | Episodic, large, US$-denominated | Nil in FY2025. A$80.5m in FY2024; A$59.4m in FY2023. | | Upfront licence fees | One-off | A$146m in FY2023 (global licence expansion) | | PRV proceeds share | One-off | A$76.5m in FY2024 (Neuren's one-third share of Acadia's PRV sale) | | Finance income | Interest on cash and term deposits | A$5.6m in H1 2026 | | Product sales / services / subscriptions | None | Not applicable | ### Value-chain position, customers and end-markets **Value-chain position:** Upstream. Neuren covers discovery, early and late clinical development (for NNZ-2591), regulatory strategy and IP ownership. For trofinetide it sits entirely upstream of its licensee's commercial operations. **Customer:** Effectively one, Acadia Pharmaceuticals (Nasdaq: ACAD), which is the sole source of royalty and milestone revenue. End users are patients with Rett syndrome and their prescribing physicians, accessed through Acadia. **End-markets:** Rare paediatric neurodevelopmental disorders: Rett syndrome (commercial), Phelan-McDermid syndrome (Phase 3), Pitt Hopkins syndrome (end of Phase 2), Angelman syndrome (Phase 2 completed), and hypoxic-ischemic encephalopathy (pre-IND). Fragile X syndrome is licensed to Acadia.

RevenueN/A
EmployeesN/A
Market CapN/A
Founded2001
Hawthorn East, Australia
Nelson

Nelson Resources Limited

Premium
Information Technology

Nelson Resources is a Perth-based, ASX-listed junior explorer. Between December 2025 and mid-2026 it pivoted from a stagnant Western Australian gold portfolio to a Nevada-centred precious-metals and critical-minerals strategy. Its flagship is now the Gold Point gold-silver project in Nevada's Walker Lane. Under an earn-in with TSX-V-listed GGL Resources, Nelson holds an initial 25% interest and can earn up to 90%. The deal consolidates the historic district under one owner for the first time in more than 140 years. Gold Point has reported pre-WWII production of about 75,000 oz Au at 20–30 g/t from 4 of 15 mapped veins. The company is pursuing a low-cost strategy: it rehabilitates historic underground workings and drills from inside them. The Cinnamon tungsten property, adjacent to Guardian Metal Resources' Pilot Mountain project, adds US critical-minerals exposure. In Western Australia, the Yarri gold project is carried by MEGA Resources under a 70:30 profit-share. Nelson is pre-resource and pre-revenue, holds about A$2.1 million in cash, and trades at a sub-cent share price. --- **Company's own description.** The FY2025 Annual Report states that the Group's principal activities "were the exploration and development of natural resources." The segment note (Note 6) states that the company "does not have any customers at this stage" and has no operating segments with discrete financial information. Recent announcements describe Nelson as a company "focused on discovering and developing natural resources." It frames Gold Point as transformative and Cinnamon as part of a critical-minerals portfolio (June 2026 quarterly). **Independent characterisation.** Nelson is a pure-play, early-stage mineral explorer. Its value lies entirely in the option value of its tenements and earn-in rights. It creates value by: 1. **Acquiring prospective ground cheaply.** It uses staged earn-ins, staking and scrip consideration rather than cash. 2. **Generating exploration results.** It reports sampling, mapping, geophysics and drilling results under the JORC Code (2012), which it hopes will re-rate the share price. 3. **Funding activity through equity placements.** This dilutes shareholders. The share count rose from about 589 million in July 2023 to about 2.79 billion by May 2026. 4. **Monetising non-core assets through partner-funded structures.** Examples are the Yarri Right to Mine Agreement with MEGA Resources and the retained 1% NSR on the Happy Jack tenement. **Revenue model.** There is no operating revenue. Reported "revenue" consists of interest income and, historically, office sub-lease income. FY2025 revenue was A$10,958, all interest (FY2025 Annual Report, Note 3). The company's only potential near-term cash inflow is its 30% share of profits from MEGA's mining at Yarri, if a mine plan is approved, ore is mined and toll-treated, and profits are distributed. This contingent stream is royalty-like in substance. **Value chain position.** Nelson sits at the very first stage of the mining value chain: grassroots-to-advanced exploration. It has no resource, reserve, processing or offtake. At Yarri, MEGA would mine and haul ore to a third-party processing plant, so Nelson would remain a passive participant. **Customer types and end markets.** There are no customers. Its prospective end markets are global gold and silver bullion markets (Gold Point, Yarri, Woodline, Tempest, Fortnum) and tungsten and copper markets (Cinnamon; copper-oxide and porphyry targets at Gold Point). Tungsten is a US-designated critical mineral.

RevenueN/A
EmployeesN/A
Market CapN/A
Founded2007
West Perth . The most recent filing, Australia
Nearmap

Nearmap Ltd

Premium
Information Technology

Nearmap has repositioned itself from an aerial imagery subscription company into a "global property intelligence company". The new positioning rests on owning the whole value chain: patented camera hardware (HyperCamera3), its own aerial capture programme, a 15-plus-year imagery archive, deep-learning feature extraction, and since 2025 claims-grade building-materials data through itel. Its two strongest franchises are government and AEC (architecture, engineering, construction) customers in Australia, where capture covers about 96.5% of the population, and property and casualty (P&C) insurance in North America, where capture covers nearly 90% of the US population. Since the 2022 take-private, Thoma Bravo has steered the company toward insurance with two acquisitions: Betterview (2023, underwriting risk analytics) and itel (2025, claims materials pricing). Those deals pit Nearmap directly against Eagleview, Vexcel and analytics specialists. The 2026 settlement of the five-year Eagleview patent litigation and the exclusive Esri ArcGIS Living Atlas imagery agreement are the two most material recent strategic events. --- **Company self-description (latest).** Nearmap describes itself in its 2026 boilerplate as a global property intelligence company that owns the entire intelligence value chain. In its words, that chain runs from high-recency geospatial capture using patented camera technology, through AI-derived analytics, to guaranteed building-materials data, giving property decisions a single trusted source of truth (Nearmap/Eagleview settlement release, May 2026). In its last listed annual reporting (FY2022), the company described itself as providing easy, instant access to high-resolution aerial imagery, city-scale 3D content, AI data sets and geospatial tools. **What it does.** Nearmap flies proprietary multi-camera systems on crewed survey aircraft over urban and peri-urban areas of Australia, New Zealand, the United States and Canada. It captures urban centres up to several times a year, historically at roughly 5.8–7.5 cm ground sample distance. The imagery is processed in the cloud into: - orthomosaic vertical imagery; - multi-angle oblique imagery (HyperCamera3 captures up to 14 angles per ground location); - panoramas; - 3D meshes and point clouds; - AI-derived vector and raster data layers, such as roof condition, roof material, solar panels, pools, vegetation and building footprints. Customers access this content through the MapBrowser web application, APIs, GIS/CAD integrations (Esri, Autodesk and others), and vertical applications for insurance (Betterview, ImpactResponse, itel NOW). **Business model and revenue model.** As a listed company, Nearmap's revenue was overwhelmingly recurring subscription (SaaS) revenue, recognised evenly over the subscription term, with ACV as the leading indicator. Product, services and licensing mix was not separately reported, but the model was effectively about 100% subscription and licensing. Post-acquisition the mix has broadened: **Subscription/licence:** MapBrowser, imagery and AI data subscriptions, Betterview platform subscriptions, and the ArcGIS Living Atlas content licence (2026). **Transactional / per-assessment:** ImpactResponse catastrophe imagery, roof measurement reports, and itel claims services (material matching, repairability analysis, pricing). **Fulfilment-linked:** itel Total Price (August 2026) offers guaranteed whole-home materials pricing backed by fulfilment, a quasi-product revenue stream. The current revenue mix by model is not publicly disclosed. **Value chain position.** Nearmap is vertically integrated across upstream (camera design and manufacture, flight operations), midstream (photogrammetry, cloud processing, archive storage) and downstream (AI analytics, workflow applications, claims data). Few competitors are integrated this far; Eagleview is the closest comparable. **Customer types and end-markets.** **Independent characterisation.** Nearmap is best understood today as a data-asset business with two monetisation layers. The first is a capture-and-archive layer with high fixed cost: aircraft hours and a camera fleet costing roughly US$1m per system, per a March 2026 Thoma Bravo interview. That cost is amortised across many subscribers. The second is an analytics and workflow layer whose incremental margin is higher and whose wallet is larger in insurance claims than in imagery viewing. The itel acquisition is the clearest signal that Thoma Bravo's value-creation thesis has moved from "sell more imagery seats" to "own the economics of the insurance claim". It also raises the company's exposure to catastrophe-year volatility and to Verisk/Xactimate channel dependence.

RevenueN/A
EmployeesN/A
Market CapN/A
Founded2007
Barangaroo, Australia
Native

Native Mineral Resources Holdings Limited

Premium
Information Technology

Native Mineral Resources is an ASX-listed junior gold producer. Since late 2024 it has turned itself from a grassroots copper-gold explorer in far-north Queensland into an operating gold miner centred on the Charters Towers district. Its core asset is the Blackjack carbon-in-leach (CIL) processing plant, which NMR bought out of administration in November 2024 under a deed of company arrangement. The plant was refurbished and back in operation by July 2025. The company describes Blackjack as one of only three processing plants in the Charters Towers region. Its strategy is to make the plant a regional "hub" fed from several sources: its own Blackjack pits, the Far Fanning, Great Britain and Granite Castle deposits, and third-party ore. Third-party feed comes through a 12-month mining right at Haoma's Podosky deposit, a profit-share JV with Great Divide Mining, and the September 2026 Stockholm JV with Citigold. Production is ramping, with a record 1,080.5 oz in August 2026. The balance sheet is very thin, however, and the company relies on short-dated debt and convertible funding. --- ### What the company does NMR explores for, mines and processes gold, with silver as a minor by-product, in north Queensland. It operates an integrated "mine-to-doré" model. Ore is mined by open-pit methods from shallow oxide and transitional pits (Blackjack South, Blackjack Mid, Podosky and, prospectively, Blackjack North and Far Fanning). The ore is trucked to the Blackjack CIL plant and processed into gold doré bars, which are smelted on site and sent to a refinery. Revenue is recognised on refined gold and silver outturn. NMR's corporate and project disclosures describe the Blackjack plant as having a 340 ktpa nameplate capacity, with a pathway to 528 ktpa from FY2029. In the June 2026 quarter it milled 67,584 dry tonnes, which annualises to about 270 kt, below nameplate. ### Company's own description In its 2025 annual report narrative and in 2026 operational releases, NMR presents itself as a gold and base-metals company whose strategy is to establish the Blackjack Processing Plant as a regional gold processing hub that can take several mineralised feed sources from across the Charters Towers region. Older annual reports (FY2022–FY2023) described the company as gold- and copper-focused and aiming to build a new Australian copper and gold mining company, centred on the Palmerville copper project in far-north Queensland. ### Independent characterisation On the evidence available, NMR is best described as a toll-capable, sub-scale, early-stage gold producer. The key features are: 1. **Single processing asset.** All revenue flows through one 340 ktpa plant. 2. **Low-grade, short-life feed so far.** The reconciled head grade reached a record of only 0.93 g/t Au in June 2026, which leaves the operation highly geared to grade improvement. 3. **Third-party ore increasingly important.** Podosky ore (Haoma) and potential Stockholm ore (Citigold) both carry profit-share or payment obligations. 4. **Thin liquidity.** Cash was A$168,000 at 30 June 2026, with an estimated 0.59 quarters of funding (Appendix 5B, June 2026 quarter). The business is effectively a leveraged bet on the A$ gold price and on NMR's ability to source higher-grade ore before its debt obligations mature. ### Revenue model | Revenue element | Nature | Share of revenue | Source | |---|---|---|---| | Gold doré sales (refined outturn) | Product sales, spot-linked commodity | About 98.9% of June-quarter FY2026 smelt revenue (A$7,765,314 of A$7,850,822) | Quarterly Activities Report, Jun 2026 | | Silver by-product | Product sales | About 1.1% (A$85,509) | Quarterly Activities Report, Jun 2026 | | Toll / JV processing economics | Profit-share on third-party ore (Great Divide Mining 50/50; Citigold Stockholm 50/50 surplus after cost recovery and an 8% margin on specified NMR costs) | Not separately disclosed | Great Divide JV term sheet; Citigold JV, 3 Sep 2026 | | Services / subscriptions / licensing | None | 0% | n/a | ### Value chain position, customers and end-markets NMR sits in upstream mining and primary processing (exploration, mining and CIL processing to doré). Refining is outsourced; the refinery counterparty is not named in the reviewed disclosures. Its customers are bullion refiners and purchasers of refined gold, and the end-market is the global gold market (investment, central bank, jewellery and technology demand). Its realised price is effectively the A$ spot gold price. NMR has not disclosed any hedge book, and none was identified in reviewed filings.

RevenueN/A
EmployeesN/A
Market CapN/A
Founded2020
Sydney, Australia

Page 220 of 482

1…219220221…482

Page 220 of 482

Go to page
Deloitte logo
Accenture logo
Oracle logo
PWC logo
EY logo
Honeywell logo